{"numRecords":"242","DataElementQueryResults":[{"publicId":"3335729","version":"1","preferredName":"Mini-Mental Status Exam Date","preferredDefinition":"The date on which the Mini-Mental Status Exam (MMSE) was performed.","longName":"MMSE_DATE","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B489B2C0-BA13-3441-E040-BB89AD43759D","latestVersionIndicator":"Yes","beginDate":"2011-12-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-12-20","modifiedBy":"COOPERM","dateModified":"2014-04-07","changeNote":"Released per approval by J.Zhao. mc 1/6/12\r\nMoved to ABTC context 4/7/14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3337055","version":"1","preferredName":"Baseline Abnormality Common Terminology Criteria for Adverse Events Version 4.0 Term Name","preferredDefinition":"Text term to describe the baseline abnormality using current Common Terminology Criteria for Adverse Events code.","longName":"BABN_CTCAE_CD","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B4A19C46-2D70-E771-E040-BB89AD431B97","latestVersionIndicator":"Yes","beginDate":"2011-12-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-12-21","modifiedBy":"FORMBUILDER","dateModified":"2014-07-15","changeNote":"Released per approval by J.Zhao. mc 1/3/12\r\nMoved to ABTC context mc 4/7/14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3337062","version":"1","preferredName":"Baseline Abnormality Adverse Event Severity Grade","preferredDefinition":"Numeric representation of the intensity and/or severity of a baseline abnormality based on the Common Terminology Criteria for Adverse Events.","longName":"BABN_CTCAE_GRD","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B4A19C46-2D96-E771-E040-BB89AD431B97","latestVersionIndicator":"Yes","beginDate":"2011-12-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-12-21","modifiedBy":"FORMBUILDER","dateModified":"2014-07-15","changeNote":"Released per approval by J.Zhao. mc 1/3/12\r\nMoved to ABTC context mc 4/7/14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3379266","version":"1","preferredName":"Antiepileptic Drug Administration Change Indicator","preferredDefinition":"A yes/no indicator to describe whether the anti-epileptic drug (AED) was changed since the last evaluation was performed.","longName":"AED_ADM_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B91A08CE-C4E2-784E-E040-BB89AD435DD1","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-02-16","modifiedBy":"COOPERM","dateModified":"2014-04-07","changeNote":"Released for ABTC per approval by J.Zhao. mc 3/1/12\r\nMoved to ABTC context mc 4/7/14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3379267","version":"1","preferredName":"Antiepileptic Drug Change From Non Enzyme Inducing To Enzyme Inducing  Administration Indicator","preferredDefinition":"A yes/no indicator to describe whether the type of anti-epileptic drug (AED) was changed from a non-enzyme inducing drug (Non-EIAD) to an enzyme inducing drug (EIAD).","longName":"AED_CH_NEI_EI_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B91A08CE-C50A-784E-E040-BB89AD435DD1","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-02-16","modifiedBy":"COOPERM","dateModified":"2014-04-07","changeNote":"Released for ABTC per approval by J.Zhao. mc 3/1/12\r\nMoved to ABTC context mc 4/7/14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3379552","version":"1","preferredName":"Corticosteroid Magnetic Resonance Imaging Timepoint Administered Indicator","preferredDefinition":"Indicator to signify whether or not a corticosteroid was being given at the time of the MRI scan.","longName":"CORT_MRI_ADM_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B92BDDE2-353B-C61C-E040-BB89AD4317D7","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-02-17","modifiedBy":"COOPERM","dateModified":"2016-07-20","changeNote":"Released for ABTC per approval by J.Zhao. mc 3/1/12 Moved to ABTC context mc 4/7/14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3379553","version":"1","preferredName":"Corticosteroid Magnetic Resonance Imaging Timepoint Administered Type","preferredDefinition":"Text term that represents the name of the corticosteroid being given at the time of the MRI scan.","longName":"CORT_MRI_ADM_TP","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B92BDDE2-3561-C61C-E040-BB89AD4317D7","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-02-17","modifiedBy":"COOPERM","dateModified":"2016-07-20","changeNote":"Released for ABTC per approval by J.Zhao. mc 3/1/12 Moved to ABTC context mc 4/7/14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3379554","version":"2","preferredName":"Corticosteroid Magnetic Resonance Imaging Timepoint Administered Dose","preferredDefinition":"The dose amount of the corticosteroid being given at the time of the MRI scan.","longName":"CORT_MRI_DOSE","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7973327F-8376-49B7-E053-F662850A32E3","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-10-30","modifiedBy":"COOPERM","dateModified":"2018-10-30","changeNote":"Released for ABTC per approval by J.Zhao. mc 3/1/12 Moved to ABTC context mc 4/7/14 Versioned to use new version of VD 10.30.18 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3379558","version":"1","preferredName":"Corticosteroid Dose Change Past Five Day Administration Indicator","preferredDefinition":"Indicator to signify whether or not the dose of corticosteroid being given has changed in the past five days.","longName":"CORT_DOSE_CH_P5D_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B92BDDE2-3636-C61C-E040-BB89AD4317D7","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-02-17","modifiedBy":"COOPERM","dateModified":"2014-04-07","changeNote":"Released for ABTC per approval by J.Zhao. mc 3/1/12\r\nMoved to ABTC context mc 4/7/14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3396684","version":"1","preferredName":"Protocol Therapy Magnetic Resonance Imaging Timepoint Begin Administration Indicator","preferredDefinition":"Indicator to signify whether or not protocol therapy had begun at the time of the scan.","longName":"PRTHR_MRI_BG_ADM_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA31FFB7-0964-BED0-E040-BB89AD432ED7","latestVersionIndicator":"Yes","beginDate":"2012-03-01","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-03-01","modifiedBy":"COOPERM","dateModified":"2014-04-07","changeNote":"Released for ABTC per approval by J.Zhao. mc 3/1/12\r\nMoved to ABTC context mc 4/7/14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3412275","version":"1","preferredName":"Agent Hold Administration Date","preferredDefinition":"The date the administration of a drug was held.","longName":"3412261v1.0:2018550v1.0","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BAD3322E-8F43-EF6C-E040-BB89AD437A2D","latestVersionIndicator":"Yes","beginDate":"2012-03-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-03-09","modifiedBy":"COOPERM","dateModified":"2017-01-17","changeNote":"Created for ABTC and released per approval by J.Zhao. mc 3/12/12 Moved to ABTC context mc 4/7/14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3419032","version":"2","preferredName":"Adverse Event Reference Number","preferredDefinition":"Numeric representation of a reference identifier for a specific adverse event within a patient record.","longName":"2752024v1.0:3419019v1.1","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E1144BD3-E96E-A3EB-E040-BB89AD430F8F","latestVersionIndicator":"Yes","beginDate":"2012-03-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-07-09","modifiedBy":"COOPERM","dateModified":"2014-04-07","changeNote":"Created for ABTC and released per approval by J.Zhao. mc 3/20/12 Versioned to extend max length per request by owner. mc 7/9/13\r\nMoved to ABTC context mc 4/7/14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3419990","version":"1","preferredName":"Off Treatment Not Death Or Progression Reason Indicator","preferredDefinition":"Indicator to signify whether or not the patient is off treatment for a reason other than death or progression.","longName":"3419989v1.0:2018320v1.0","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BBC8576A-7A1B-BB2B-E040-BB89AD4354F8","latestVersionIndicator":"Yes","beginDate":"2012-03-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-03-21","modifiedBy":"MORENOC","dateModified":"2018-04-18","changeNote":"Replaced VD Assessments Ind-2 2018320v1.0 with VD ID#3506068 - Yes No Indicator - dbw\r\nMoved to ABTC context mc 4/7/14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3419996","version":"1","preferredName":"Progression Pathologic Confirmed Diagnosis Indicator","preferredDefinition":"Indicator to signify whether or not disease progression was confirmed by pathologic diagnosis.","longName":"3419992v1.0:2404918v1.0","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BBC91C0B-55E8-5EEE-E040-BB89AD4344C9","latestVersionIndicator":"Yes","beginDate":"2012-03-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-03-21","modifiedBy":"COOPERM","dateModified":"2014-04-23","changeNote":"Replaced VD Diagnosis Ind-2 2404918v1 with VD ID#3506068 - Yes No Indicator  - dbw Moved to ABTC context mc 4/7/14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3420687","version":"1","preferredName":"Additional Dose Administered Count","preferredDefinition":"Number that represents a count of the additional doses the patient received.","longName":"ADD_DOSE_ADM_CT","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BBDD16D2-27AE-4A2D-E040-BB89AD435DEA","latestVersionIndicator":"Yes","beginDate":"2012-03-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-03-22","modifiedBy":"COOPERM","dateModified":"2014-04-07","changeNote":"Created for ABTC per request by J.Zhao. mc 3/22/12\r\nMoved to ABTC context mc 4/7/14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3743221","version":"1","preferredName":"Brain Tumor Histologic Classification Code","preferredDefinition":"Numeric representation for categories related to histologic diagnosis.","longName":"2188996v1.0:3743220v1.0","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DBD1BEA5-94FC-7E5A-E040-BB89AD4348D2","latestVersionIndicator":"Yes","beginDate":"2013-05-03","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-05-03","modifiedBy":"COOPERM","dateModified":"2014-04-07","changeNote":"Created for ABTC form per request by J.Zhao. mc 5/3/13\r\nMoved to ABTC Context mc 4/7/14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3761958","version":"1","preferredName":"Tumor Tissue Form Initial Resection Glioblastoma Diagnosis Pathologist Signed Indicator","preferredDefinition":"Indicator to signify whether or not the patient has a tumor tissue form indicating availability of archived tissue from initial resection at diagnosis of glioblastoma completed and signed by a pathologist.","longName":"3761916v1.0:3506068v1.0","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DCB10B25-E517-E74B-E040-BB89AD434731","latestVersionIndicator":"Yes","beginDate":"2013-05-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-05-14","modifiedBy":"TSESU","dateModified":"2019-05-31","changeNote":"Created for ABTC eligibility checklist for the 1202 Mk-1775 study per request by J.Zhao. mc 5/14/13 Released per approval by Jason. mc 6/13/13 Moved to ABTC Context mc 4/8/14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3761959","version":"1","preferredName":"Glioblastoma Histologic Diagnosis Indicator","preferredDefinition":"Indicator to signify whether or not the patient has a histologically proven glioblastoma.","longName":"3761919v1.0:3506068v1.0","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DCB10B25-E53D-E74B-E040-BB89AD434731","latestVersionIndicator":"Yes","beginDate":"2013-05-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-05-14","modifiedBy":"FORMBUILDER","dateModified":"2018-05-14","changeNote":"Created for ABTC eligibility checklist for the 1202 Mk-1775 study per request by J.Zhao. mc 5/14/13 Released per approval by Jason. mc 6/13/13\r\nMoved to ABTC Context mc 4/8/14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3761960","version":"1","preferredName":"Prior Therapy Other Than Glucocorticoid Therapy History Indicator","preferredDefinition":"Indicator to signify whether or not the patient had prior therapy other than glucocorticoid therapy.","longName":"3761922v1.0:3506068v1.0","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DCB10B25-E563-E74B-E040-BB89AD434731","latestVersionIndicator":"Yes","beginDate":"2013-05-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-05-14","modifiedBy":"COOPERM","dateModified":"2014-04-08","changeNote":"Created for ABTC eligibility checklist for the 1202 Mk-1775 study per request by J.Zhao. mc 5/14/13\r\nMoved to ABTC Context mc 4/8/14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3761965","version":"1","preferredName":"Prior Planned Treatment with Radiation Therapy and Concomitant Temozolomide Indicator","preferredDefinition":"Indicator to signify whether or not the patient received planned treatment with radiation therapy and concomitant temozolomide at least 28 days but no more than 49 days prior to starting treatment on this study.","longName":"3761926v1.0:3506068v1.0","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DCB1363C-F184-282F-E040-BB89AD437D7E","latestVersionIndicator":"Yes","beginDate":"2013-05-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-05-14","modifiedBy":"COOPERM","dateModified":"2014-04-08","changeNote":"Created for ABTC eligibility checklist for the 1202 Mk-1775 study per request by J.Zhao. mc 5/14/13 Released per approval by Jason. mc 6/13/13\r\nMoved to ABTC Context mc 4/8/14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3761966","version":"1","preferredName":"Prior Glioblastoma Histologic Diagnosis Progressive Or Recurrent Disease Post Radiation Therapy And/Or Chemotherapy Indicator","preferredDefinition":"Indicator to signify whether or not the patient has prior histologically proven glioblastoma that is progressive or recurrent following radiation therapy and/or chemotherapy.","longName":"3761930v1.0:3506068v1.0","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DCB1363C-F1B9-282F-E040-BB89AD437D7E","latestVersionIndicator":"Yes","beginDate":"2013-05-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-05-14","modifiedBy":"TSESU","dateModified":"2018-08-28","changeNote":"Created for ABTC eligibility checklist for the 1202 Mk-1775 study per request by J.Zhao. mc 5/14/13 Released per approval by Jason. mc 6/13/13 Moved to ABTC Context mc 4/8/14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3761969","version":"1","preferredName":"Repeat Clinically Indicated Surgical Procedure Performed Indicator","preferredDefinition":"Indicator to signify whether or not the patient is undergoing repeat surgery that is clinically indicated.","longName":"3761933v1.0:3506068v1.0","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DCB1363C-F23D-282F-E040-BB89AD437D7E","latestVersionIndicator":"Yes","beginDate":"2013-05-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-05-14","modifiedBy":"WISEM","dateModified":"2021-02-04","changeNote":"Created for ABTC eligibility checklist for the 1202 Mk-1775 study per request by J.Zhao. mc 5/14/13 Released per approval by Jason. mc 6/13/13\r\nMoved to ABTC Context mc 4/8/14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3761970","version":"1","preferredName":"Progressive or Recurrent Glioblastoma Measured by Contrast Enhanced MRI Within 21 Days Start Treatment Indicator","preferredDefinition":"Indicator to signify whether or not the patient has measurable contrast-enhancing progressive or recurrent glioblastoma by MRI within 21 days of starting treatment.","longName":"3761937v1.0:3506068v1.0","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DCB19E30-740A-85DC-E040-BB89AD4308BF","latestVersionIndicator":"Yes","beginDate":"2013-05-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-05-14","modifiedBy":"TSESU","dateModified":"2018-08-28","changeNote":"Created for ABTC eligibility checklist for the 1202 Mk-1775 study per request by J.Zhao. mc 5/14/13 Released per approval by Jason. mc 6/13/13 Moved to ABTC Context mc 4/8/14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3761972","version":"1","preferredName":"Prior Therapeutic Procedure Timespan Completion Indicator","preferredDefinition":"Indicator to signify whether or not a time period has passed since the completion of the associated prior therapy.","longName":"3761940v1.0:3506068v1.0","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DCB1C682-33CD-4B3A-E040-BB89AD430E66","latestVersionIndicator":"Yes","beginDate":"2013-05-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-05-14","modifiedBy":"CLOHNES","dateModified":"2023-02-16","changeNote":"Created for ABTC eligibility checklist for the 1202 Mk-1775 study per request by J.Zhao. mc 5/14/13 Released per approval by Jason. mc 6/13/13 Moved to ABTC Context mc 4/8/14","administrativeNotes":"2/16/23 added AQT for URCC ticket request CADSR0002063 cjl.","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3761973","version":"1","preferredName":"Enzyme Induction Anticonvulsant Therapy Discontinue 10 Days Prior To Study Start Indicator","preferredDefinition":"Indicator to signify whether or not the patient is receiving enzyme-inducing anticonvulsant drugs and if so, has been off of them for 10 days prior to study start.","longName":"3761948v1.0:3506036v1.0","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DCB1FB1A-940B-3870-E040-BB89AD435B2A","latestVersionIndicator":"Yes","beginDate":"2013-05-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-05-14","modifiedBy":"TSESU","dateModified":"2017-04-03","changeNote":"Created for ABTC eligibility checklist for the 1202 Mk-1775 study per request by J.Zhao. mc 5/14/13 Released per approval by Jason. mc 6/13/13 Moved to ABTC Context mc 4/8/14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3761974","version":"1","preferredName":"Anticoagulant Agent Not Low Molecular Weight Heparin Administered Indicator","preferredDefinition":"Indicator to signify whether or not the patient is receiving anti-coagulants other than low-molecular weight heparin.","longName":"3761951v1.0:3506068v1.0","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DCB1C682-342F-4B3A-E040-BB89AD430E66","latestVersionIndicator":"Yes","beginDate":"2013-05-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-05-14","modifiedBy":"TSESU","dateModified":"2017-09-20","changeNote":"Created for ABTC eligibility checklist for the 1202 Mk-1775 study per request by J.Zhao. mc 5/14/13 Released per approval by Jason. mc 6/13/13 Moved to ABTC Context mc 4/8/14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3771291","version":"1","preferredName":"Radiography Disease Progression Treatment Response Type","preferredDefinition":"Text term to describe the kind of response progression that was documented radiologically.","longName":"3761955v1.0:2187830v1.0","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DD695E48-A61C-1F03-E040-BB89AD436112","latestVersionIndicator":"Yes","beginDate":"2013-05-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-05-23","modifiedBy":"COOPERM","dateModified":"2014-04-08","changeNote":"Created for ABTC eligibility checklist for the 1202 Mk-1775 study per request by J.Zhao. mc 5/14/13 Released per approval by Jason. mc 6/13/13\r\nMoved to ABTC Context mc 4/8/14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3771311","version":"1","preferredName":"Concurrent Malignant Neoplasm Occurrence Indicator","preferredDefinition":"Indicator to signify whether or not the patient has a concurrent malignancy.","longName":"3771294v1.0:3506068v1.0","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DD695E48-A668-1F03-E040-BB89AD436112","latestVersionIndicator":"Yes","beginDate":"2013-05-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-05-23","modifiedBy":"COBARRUBIAK","dateModified":"2019-03-11","changeNote":"Created for ABTC eligibility checklist for the 1202 Mk-1775 study per request by J.Zhao. mc 5/14/13 Released per approval by Jason. mc 6/13/13 Moved to ABTC Context mc 4/8/14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3855896","version":"1","preferredName":"Protocol Temozolomide Dose","preferredDefinition":"The assigned dose of temozolomide for the given period.","longName":"PROT_TMZ_DOSE","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E3FF937D-A178-EC4E-E040-BB89AD43511E","latestVersionIndicator":"Yes","beginDate":"2013-08-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-08-15","modifiedBy":"PROSVIROVAB","dateModified":"2019-01-10","changeNote":"Created for ABTC study in Rave per request by J.Zhao. mc 8/15/2013\r\nMoved to ABTC Context mc 4/8/14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4162687","version":"1","preferredName":"Surgical Treatment Timepoint and Assigned Dose Schedule Type","preferredDefinition":"Text term to describe the assigned dose schedule as related to the timing of surgical treatment.","longName":"SURG_TMP_DOSE_SCH_TP","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F2B332C0-867F-97A1-E040-BB89AD431DC4","latestVersionIndicator":"Yes","beginDate":"2014-02-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2014-02-18","modifiedBy":"COOPERM","dateModified":"2016-11-08","changeNote":"Created for ABTC 1301 study in Rave per request by J.Zhao. mc 2/18/2014 Moved to ABTC Context mc 4/8/14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4174171","version":"1","preferredName":"Tumor Tissue Adequate Amount Obtained During Resection Descriptive Value","preferredDefinition":"Text term and number that represents the amount of tumor tissue obtained during surgery that met protocol defined thresholds.","longName":"TIS_ADQ_AMT_RESCT_VL","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F340E526-5F5D-1173-E040-BB89AD4319E8","latestVersionIndicator":"Yes","beginDate":"2014-02-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2014-02-25","modifiedBy":"CLOHNES","dateModified":"2023-02-24","changeNote":"Created for ABTC 1301 study in Rave per request by J.Zhao. mc 2/25/2014\r\nMoved to ABTC Context mc 4/8/14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4174181","version":"1","preferredName":"Prior Relapse Treatment Administered Count","preferredDefinition":"Numeric representation of how many times a patient had recurrent disease that required treatment.","longName":"PR_RLPS_TRMT_ADM_CT","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F34083EE-F5F9-CF31-E040-BB89AD433DA9","latestVersionIndicator":"Yes","beginDate":"2014-02-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2014-02-25","modifiedBy":"COOPERM","dateModified":"2014-04-08","changeNote":"Created for ABTC 1301 study in Rave per request by J.Zhao. mc 2/25/2014\r\nMoved to ABTC Context mc 4/8/14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4174243","version":"1","preferredName":"Prior Treatment Bevacizumab Or VEGFR Inhibitor Indicator","preferredDefinition":"Indicator of whether or not the patient has had prior treatment with Beavacizumab or VEGFR inhibitors.","longName":"PTRMT_BVCZ_VEGFR_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3418CE9-2CBF-356C-E040-BB89AD4370F5","latestVersionIndicator":"Yes","beginDate":"2014-02-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2014-02-25","modifiedBy":"COOPERM","dateModified":"2014-04-08","changeNote":"Created for ABTC 1301 study in Rave per request by J.Zhao. mc 2/25/2014\r\nMoved to ABTC Context mc 4/8/14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4174374","version":"1","preferredName":"Personal Medical History Hematologic Renal Hepatic Dysfunction Indicator","preferredDefinition":"Indicator of whether or not the patient has a history of hematologic, renal or hepatic dysfunction.","longName":"HIST_HEM_RNL_HEP_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3418CE9-2CF9-356C-E040-BB89AD4370F5","latestVersionIndicator":"Yes","beginDate":"2014-02-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2014-02-25","modifiedBy":"COOPERM","dateModified":"2014-04-08","changeNote":"Created for ABTC 1301 study in Rave per request by J.Zhao. mc 2/25/2014\r\nMoved to ABTC Context mc 4/8/14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4174772","version":"1","preferredName":"Personal Medical History Last Six Months Heart Brain Or Lung Disease or Disorder Indicator","preferredDefinition":"Indicator of whether or not the patient has a history, in the last six months of medical conditions related to the heart, brain or lungs.","longName":"HIST_HRT_BR_LNG_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F341BB92-3445-F3D7-E040-BB89AD4313F6","latestVersionIndicator":"Yes","beginDate":"2014-02-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2014-02-25","modifiedBy":"COOPERM","dateModified":"2014-04-21","changeNote":"Created for ABTC 1301 study in Rave per request by J.Zhao. mc 2/25/2014 Moved to ABTC Context mc 4/8/14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4174844","version":"1","preferredName":"Therapeutic Procedure Bisphophonates Less Than 30 Days Prior To Study Drug First Administration Indicator","preferredDefinition":"Indicator of whether or not the patient started receiving bisphosphonates less than 30 days prior to the first administration study drug.","longName":"BISPH_TRMT_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F341BB92-34D9-F3D7-E040-BB89AD4313F6","latestVersionIndicator":"Yes","beginDate":"2014-02-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2014-02-25","modifiedBy":"COOPERM","dateModified":"2014-04-08","changeNote":"Created for ABTC 1301 study in Rave per request by J.Zhao. mc 2/25/2014\r\nMoved to ABTC Context mc 4/8/14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4174861","version":"1","preferredName":"Surgical Procedure Greater Than or Equal To 350 Milligrams Enhancing Lesion Or Non Enhancing Lesion Resection Yes No Indicator","preferredDefinition":"Indicator of whether or not the surgeon expects to resect at least 350 mg of tumor from enhancing tumor and at least 350 mg from non-enhancing tumor with low risk of inducing neurological injury.","longName":"RSCT_350_ENH_TMR_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F341D8AD-2CAA-937F-E040-BB89AD43262B","latestVersionIndicator":"Yes","beginDate":"2014-02-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2014-02-25","modifiedBy":"COOPERM","dateModified":"2014-04-08","changeNote":"Created for ABTC 1301 study in Rave per request by J.Zhao. mc 2/25/2014\r\nMoved to ABTC Context mc 4/8/14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4174862","version":"1","preferredName":"Surgical Procedure Greater Than or Equal To 1000 Milligrams Enhancing Lesion and 350 Milligrams Non Enhancing Lesion Excision Indicator","preferredDefinition":"Indicator of whether or not the surgeon expects to resect at least 1000 mg of tumor from enhancing tumor and at least 350 mg from non-enhancing tumor with low risk of inducing neurological injury.","longName":"RSC_1000_ENH_TMR_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F341D8AD-2D18-937F-E040-BB89AD43262B","latestVersionIndicator":"Yes","beginDate":"2014-02-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2014-02-25","modifiedBy":"COOPERM","dateModified":"2014-04-08","changeNote":"Created for ABTC 1301 study in Rave per request by J.Zhao. mc 2/25/2014\r\nMoved to ABTC Context mc 4/8/14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4174863","version":"1","preferredName":"Glioblastoma Slide Greater Than or Equal To Twenty From Prior Surgery Present Indicator","preferredDefinition":"Indicator of whether or not the patient has at least 20 (preferably 40) slides of archival tumor tissue from a prior surgery demonstrating GBM.","longName":"GBMSL_20_PR_SURG_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F341BB92-3548-F3D7-E040-BB89AD4313F6","latestVersionIndicator":"Yes","beginDate":"2014-02-25","endDate":null,"createdBy":"COOPERM","dateCreated":"2014-02-25","modifiedBy":"COOPERM","dateModified":"2014-04-08","changeNote":"Created for ABTC 1301 study in Rave per request by J.Zhao. mc 2/25/2014\r\nMoved to ABTC Context mc 4/8/14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4182069","version":"1","preferredName":"Laboratory Procedure Activated Partial Thromboplastin Time Date","preferredDefinition":"The date on which an activated partial thromboplastin time laboratory test was obtained.","longName":"LAB_APTT_DT","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F36A2E6C-D8D0-314A-E040-BB89AD430B3F","latestVersionIndicator":"Yes","beginDate":"2014-02-27","endDate":null,"createdBy":"COOPERM","dateCreated":"2014-02-27","modifiedBy":"MORENOC","dateModified":"2016-10-20","changeNote":"Created for ABTC 1301 study in Rave per request by J.Zhao. mc 2/27/2014\r\nMoved to ABTC Context mc 4/8/14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4182086","version":"1","preferredName":"Laboratory Procedure Partial Thromboplastin Time Date","preferredDefinition":"The date on which a partial thromboplastin time laboratory test was obtained.","longName":"LAB_PTT_DT","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3698997-0332-76CC-E040-BB89AD43338F","latestVersionIndicator":"Yes","beginDate":"2014-02-27","endDate":null,"createdBy":"COOPERM","dateCreated":"2014-02-27","modifiedBy":"COOPERM","dateModified":"2014-04-08","changeNote":"Created for ABTC 1301 study in Rave per request by J.Zhao. mc 2/27/2014\r\nMoved to ABTC Context mc 4/8/14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4265283","version":"2","preferredName":"Heart LVEF Test Percentage Upper Limit of Normal Value","preferredDefinition":"The value in percentage for the ejection fraction of the left ventricle of the heart which is measured as an institutional standard for the highest value considered as a normal test result.","longName":"HR_LVEF_UPPER_LMT_VL","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"609EFEC6-218D-646F-E053-F662850AC5D3","latestVersionIndicator":"Yes","beginDate":"2014-04-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-12-18","modifiedBy":"COOPERM","dateModified":"2017-12-18","changeNote":"Created for ABTC 1302 study in Rave per request by J.Fisher. mc 4/8/14 Versioned VD/CDE to use Number data type. 12.18.17 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4265611","version":"1","preferredName":"Surgical Procedure Greater Than or Equal To 500 Milligrams Enhancing Lesion and 100 Milligrams Non Enhancing Lesion Excision Indicator","preferredDefinition":"Indicator of whether or not the surgeon expects to resect at least 500 mg of tumor from enhancing tumor and at least 100 mg from non-enhancing tumor with low risk of inducing neurological injury.","longName":"RSC_500_ENH_TMR_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F6A23058-E29A-8179-E040-BB89AD434D47","latestVersionIndicator":"Yes","beginDate":"2014-04-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2014-04-09","modifiedBy":"COOPERM","dateModified":"2014-05-02","changeNote":"Created for ABTC 1302 study in Rave per request by J.Fisher. mc 4/9/14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4265612","version":"1","preferredName":"Tumor Sample Chromogenic in situ Hybridization Epidermal Growth Factor Receptor Gene Amplification Indicator","preferredDefinition":"Indicator of whether or not the tumor sample has evidence of Epidermal Growth Factor Receptor (EGFR) gene amplification by Chromogenic in situ Hybridization (CISH).","longName":"TMR_EGFR_GENEAMP_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F6A23058-E2C0-8179-E040-BB89AD434D47","latestVersionIndicator":"Yes","beginDate":"2014-04-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2014-04-09","modifiedBy":"TSESU","dateModified":"2017-04-10","changeNote":"Created for ABTC 1302 study in Rave per request by J.Fisher. mc 4/9/14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4265613","version":"1","preferredName":"Initial Diagnosis Resection Paraffin Embedded Tissue Available Indicator","preferredDefinition":"Indicator of whether or not paraffin embedded tissue is available from initial surgical resection at diagnosis (prior to any treatment).","longName":"INT_RSECT_PETIS_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F6A23058-E2E6-8179-E040-BB89AD434D47","latestVersionIndicator":"Yes","beginDate":"2014-04-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2014-04-09","modifiedBy":"COOPERM","dateModified":"2014-04-23","changeNote":"Created for ABTC 1302 study in Rave per request by J.Fisher. mc 4/9/14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4265614","version":"1","preferredName":"Diagnostic Electrocardiogram 12 Lead Placement Performed Date","preferredDefinition":"The date on which a diagnostic, 12-lead (placement unspecified) electrocardiogram was performed.","longName":"DIAG_12L_ECG_PERF_DT","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F6A23058-E30C-8179-E040-BB89AD434D47","latestVersionIndicator":"Yes","beginDate":"2014-04-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2014-04-09","modifiedBy":"COOPERM","dateModified":"2014-04-23","changeNote":"Created for ABTC 1302 study in Rave per request by J.Fisher. mc 4/9/14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4273651","version":"1","preferredName":"Recurrent Tumor Prior EGFRvIII Vaccine Positive EGFR Gene Amplification Indicator","preferredDefinition":"Indicator of whether or not the recurrent tumor is positive for EGFR gene amplicication in patients with prior EGFRvIII vaccine.","longName":"RECUR_TMR_EGFR_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F7301AD5-846C-2E3B-E040-BB89AD4320B6","latestVersionIndicator":"Yes","beginDate":"2014-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2014-04-16","modifiedBy":"COOPERM","dateModified":"2014-04-23","changeNote":"Created for ABTC 1302 study in Rave per request by J.Fisher. mc 4/16/14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4273680","version":"1","preferredName":"P-glycoprotein Inhibitor Administered Indicator","preferredDefinition":"Indicator of whether or not P-glycoprotein inhibitor was given.","longName":"PGPINHIBITOR_ADM_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F7301AD5-84DE-2E3B-E040-BB89AD4320B6","latestVersionIndicator":"Yes","beginDate":"2014-04-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2014-04-16","modifiedBy":"TYRRELLM","dateModified":"2023-12-20","changeNote":"Created for ABTC 1302 study in Rave per request by J.Fisher. mc 4/16/14","administrativeNotes":"12.20.2023 Added AQT per request ticket CADSR0003202_mmt","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4280551","version":"1","preferredName":"Clinically Indicated Surgical Procedure Performed Indicator","preferredDefinition":"Indicator to signify whether or not the patient is undergoing surgery that is clinically indicated.","longName":"CLIN_SURG_PERF_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F7B75D19-970F-3807-E040-BB89AD43680F","latestVersionIndicator":"Yes","beginDate":"2014-04-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2014-04-23","modifiedBy":"TSESU","dateModified":"2019-07-31","changeNote":"Created for ABTC RAVE study per request by J.Zhao. mc 4/23/14","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4701491","version":"1","preferredName":"Supratentorial High Grade Glioma Histologic Diagnosis Progressive Or Recurrent Disease Post Radiation Therapy And Chemotherapy Indicator","preferredDefinition":"Indicator to signify whether or not there is a presence of histologically proven supratentorial high grade glioma that is progressive or recurrent following radiation therapy and chemotherapy.","longName":"4701490v1.0:3506068v1.0","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0E382F82-01CF-0F58-E050-BB89AD431365","latestVersionIndicator":"Yes","beginDate":"2015-02-03","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-02-03","modifiedBy":"TSESU","dateModified":"2017-11-29","changeNote":"Created for ABTC 1401 protocol per request by J.Zhao. mc 2/3/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4701905","version":"1","preferredName":"Stable Therapeutic Corticosteroid Regimen Five Day Prior to Baseline Magnetic Resonance Imaging Indicator","preferredDefinition":"Indicator of whether or not the patient was maintained on a stable corticosteroid regimen for five days prior to the baseline MRI.","longName":"4701500v1.0:3506068v1.0","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0E49DE33-7FA0-CF54-E050-BB89AD433E74","latestVersionIndicator":"Yes","beginDate":"2015-02-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-02-04","modifiedBy":"COOPERM","dateModified":"2015-02-23","changeNote":"Created for ABTC 1401 study in Rave per request by J.Zhao. mc 2/5/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4701906","version":"1","preferredName":"Surgical Procedure Greater Than or Equal To 100 Milligrams Enhancing Tumor And 100 Milligrams Non Enhancing Tumor Resection Indicator","preferredDefinition":"Indicator of whether or not the resection will include at least 0.10 cm3 (100 mg) of tumor from enhancing tumor and at least 0.10 cm3 (100 mg) from non-enhancing tumor.","longName":"4701904v1.0:3506068v1.0","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0E49DE33-7FC9-CF54-E050-BB89AD433E74","latestVersionIndicator":"Yes","beginDate":"2015-02-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-02-04","modifiedBy":"TSESU","dateModified":"2018-09-10","changeNote":"Created for ABTC 1401 study in Rave per request by J.Zhao. mc 2/5/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4701907","version":"1","preferredName":"Prior Gastrointestinal Surgical Procedure Or Disease Interference With Study Drug Absorption Indicator","preferredDefinition":"Indicator of whether or not prior gastrointestinal surgery was performed or disease was present that might interfere with absorption of the study drug or drugs.","longName":"4701577v1.0:3506068v1.0","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0E49DE33-7FEF-CF54-E050-BB89AD433E74","latestVersionIndicator":"Yes","beginDate":"2015-02-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-02-04","modifiedBy":"KUMMEROA","dateModified":"2022-08-31","changeNote":"Created for ABTC 1401 study in Rave per request by J.Zhao. mc 2/5/15","administrativeNotes":"2022.8.31 AQT added per ticket request CADSR-TASK0001488. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4718833","version":"1","preferredName":"Agent Moderate Or Strong CYP2C9 Inducer Taken Indicator","preferredDefinition":"Indicator of whether or not the patient was taking any moderate or strong CYP2C9 inducers.","longName":"4718823v1.0:3506068v1.0","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F3AEDF0-C480-1580-E050-BB89AD43512C","latestVersionIndicator":"Yes","beginDate":"2015-02-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-02-16","modifiedBy":"MARTINEZW","dateModified":"2017-08-11","changeNote":"Created for ABTC 1401 study in Rave per request by J.Zhao. mc 2/16/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4718834","version":"1","preferredName":"Agent CYP1A2 Substrate With Narrow Therapeutic Index Received Indicator","preferredDefinition":"Indicator of whether or not the patient was taking any CYP1A2 substrates with narrow therapeutic indicies.","longName":"4718826v1.0:3506068v1.0","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F3AA3FF-A692-2CAD-E050-BB89AD437EBA","latestVersionIndicator":"Yes","beginDate":"2015-02-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-02-16","modifiedBy":"CARPSE","dateModified":"2015-05-14","changeNote":"Created for ABTC 1401 study in Rave per request by J.Zhao. mc 2/16/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4718835","version":"1","preferredName":"Agent CYP2C9 Substrate With Narrow Therapeutic Index Received Indicator","preferredDefinition":"Indicator of whether or not the patient was taking any CYP2C9 substrates with narrow therapeutic indicies.","longName":"4718829v1.0:3506068v1.0","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F3AA3FF-A6B8-2CAD-E050-BB89AD437EBA","latestVersionIndicator":"Yes","beginDate":"2015-02-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-02-16","modifiedBy":"COOPERM","dateModified":"2015-02-23","changeNote":"Created for ABTC 1401 study in Rave per request by J.Zhao. mc 2/16/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4718836","version":"1","preferredName":"Agent CYP2C19 Substrate With Narrow Therapeutic Index Received Indicator","preferredDefinition":"Indicator of whether or not the patient was taking any CYP2C19 substrates with narrow therapeutic indicies.","longName":"4718832v1.0:3506068v1.0","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F3AA3FF-A6DE-2CAD-E050-BB89AD437EBA","latestVersionIndicator":"Yes","beginDate":"2015-02-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-02-16","modifiedBy":"COOPERM","dateModified":"2015-02-23","changeNote":"Created for ABTC 1401 study in Rave per request by J.Zhao. mc 2/16/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4971164","version":"1","preferredName":"Eligibility Criteria Capable of Receiving Gadolinium Dye During MRI Indicator","preferredDefinition":"Eligibility criteria indicator of whether or not a patient is capable of receiving gadolinium dye during an MRI scan.","longName":"GADOLINIUM_MRI_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1D4E1411-1FA7-8C78-E050-BB89AD437593","latestVersionIndicator":"Yes","beginDate":"2015-08-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-08-14","modifiedBy":"COOPERM","dateModified":"2015-08-31","changeNote":"Created for 1403 study in Rave per request by J.Zhao. mc 8/14/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4971165","version":"1","preferredName":"Eligibility Criteria Last Five Years Prior Malignant Neoplasm Indicator","preferredDefinition":"Eligibility criteria indicator of whether or not the patient had a prior malignancy within the last five years.","longName":"PRIOR_MALIG_L5YR_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1D4E1411-1FDE-8C78-E050-BB89AD437593","latestVersionIndicator":"Yes","beginDate":"2015-08-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-08-14","modifiedBy":"COOPERM","dateModified":"2015-08-24","changeNote":"Created for 1403 study in Rave per request by J.Zhao. mc 8/14/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4971171","version":"1","preferredName":"Eligibility Criteria Known Sensitivity Study Drug or Excipient History Indicator","preferredDefinition":"Eligibility criteria indicator of whether or not the patient has a known allergic reaction to the study drug or related formulations.","longName":"KNOWN_SENS_DRUG_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1D4E5426-833A-E489-E050-BB89AD431072","latestVersionIndicator":"Yes","beginDate":"2015-08-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-08-14","modifiedBy":"SPRINGERL","dateModified":"2021-11-23","changeNote":"Created for 1403 study in Rave per request by J.Zhao. mc 8/14/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4971173","version":"1","preferredName":"Eligibility Criteria Histologically Confirmed High Grade Glioma Indicator","preferredDefinition":"Eligibility criteria indicator of whether or not the patient has histologically confirmed by pathology WHO grade III or IV glioma.","longName":"HIGH_GRD_GLIOMA_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1D4E612B-F3D3-E22A-E050-BB89AD431F32","latestVersionIndicator":"Yes","beginDate":"2015-08-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-08-14","modifiedBy":"CARPIOJ","dateModified":"2021-03-11","changeNote":"Created for 1403 study in Rave per request by J.Zhao. mc 8/14/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4971191","version":"1","preferredName":"Eligibility Criteria Postoperative Treatment Included 80 Percent Standard Radiation Therapy and Concomitant Therapy Temozolomide Indicator","preferredDefinition":"Eligibility criteria indicator of whether or not the patient's post-operative treatment included at least 80% of standard radiation and concomitant temozolomide.","longName":"POSTOP_TREATMT_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1D4E612B-F3F9-E22A-E050-BB89AD431F32","latestVersionIndicator":"Yes","beginDate":"2015-08-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-08-14","modifiedBy":"COOPERM","dateModified":"2015-09-02","changeNote":"Created for 1403 study in Rave per request by J.Zhao. mc 8/14/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4971192","version":"1","preferredName":"Eligibility Criteria Prior Chemotherapy or Immunotherapy or Biological Agent or Hormone Therapy for Brain Tumor Other Than Gliadel Wafers Or Therapeutic Glucocorticoid  Indicator","preferredDefinition":"Eligibility criteria indicator of whether or not the patient had any other prior chemotherapy, immunotherapy or therapy with biologic agent (including immunotoxins, immunoconjugates, antisense, peptide receptor antagonists, interferons, interleukins, TIL, LAK or gene therapy), or hormonal therapy for their brain tumor other than prior Gliadel Wafers or glucocorticoid therapy.","longName":"BRAIN_THERAPY_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1D4E612B-F41F-E22A-E050-BB89AD431F32","latestVersionIndicator":"Yes","beginDate":"2015-08-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-08-14","modifiedBy":"COOPERM","dateModified":"2015-09-02","changeNote":"Created for 1403 study in Rave per request by J.Zhao. mc 8/14/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4971211","version":"1","preferredName":"Eligibility Criteria Current Dexamethasone or Equivalent Alternative Corticosteroid Indicator","preferredDefinition":"Eligibility criteria indicator of whether or not the patient is receiving dexamethasone or equivalent of an alternative corticosteroid.","longName":"CURRENT_DEXAMETH_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1D4E612B-F445-E22A-E050-BB89AD431F32","latestVersionIndicator":"Yes","beginDate":"2015-08-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-08-14","modifiedBy":"KUMMEROA","dateModified":"2023-03-28","changeNote":"Created for 1403 study in Rave per request by J.Zhao. mc 8/14/15","administrativeNotes":"2023.3.28 AQT added per ticket request CADSR0002221. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4971251","version":"1","preferredName":"Dexamethasone Daily Dose Value","preferredDefinition":"Numeric representation of the daily dose of dexamethasone that the patient is receiving.","longName":"DEXAMETH_DAY_DOSE_VL","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1D4E9164-823F-BC25-E050-BB89AD43743D","latestVersionIndicator":"Yes","beginDate":"2015-08-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-08-14","modifiedBy":"COOPERM","dateModified":"2015-09-02","changeNote":"Created for 1403 study in Rave per request by R.Marasigan. mc 8/14/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4993814","version":"1","preferredName":"Eligibility Criteria Histologically Confirmed Progressive Or Recurrent Glioblastoma Following Radiation Therapy and Temozolomide Indicator","preferredDefinition":"A question about whether or not the patient has histologically confirmed progressive or recurrent glioblastoma following raditation therapy and temozolomide.","longName":"4993779v1.0:3506068v1.0","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1EA1AC3D-49D7-2996-E050-BB89AD433AFF","latestVersionIndicator":"Yes","beginDate":"2015-08-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-08-31","modifiedBy":"COOPERM","dateModified":"2015-09-02","changeNote":"Created for 1402 study in Rave per request by R.Marasigan. mc 8/31/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4993815","version":"1","preferredName":"Eligibility Criteria MGMT Methylation Status Available Indicator","preferredDefinition":"Indicator of whether or not the patient has tumor MGMT methylation status available.","longName":"4993783v1.0:3506068v1.0","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1EA1AC3D-49FD-2996-E050-BB89AD433AFF","latestVersionIndicator":"Yes","beginDate":"2015-08-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-08-31","modifiedBy":"TSESU","dateModified":"2020-08-21","changeNote":"Created for 1402 study in Rave per request by R.Marasigan. mc 8/31/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4993816","version":"1","preferredName":"Eligibility Criteria First Recurrence Glioblastoma Following Radiation Therapy and Temozolomide Indicator","preferredDefinition":"Indicator of whether or not the patient is in the first recurrence of glioblastoma following radiation therapy and temozolomide.","longName":"4993786v1.0:3506068v1.0","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1EA1AC3D-4A2F-2996-E050-BB89AD433AFF","latestVersionIndicator":"Yes","beginDate":"2015-08-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-08-31","modifiedBy":"CARTERS","dateModified":"2021-01-22","changeNote":"Created for 1402 study in Rave per request by R.Marasigan. mc 8/31/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4993817","version":"1","preferredName":"Eligibility Criteria Prior Antiangiogenesis Therapy Except Bevacizumab Administered Indicator","preferredDefinition":"Indicator of whether or not the patient has received prior antiangiogenesis therapy except for bevacizumab.","longName":"4993789v1.0:3506068v1.0","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1EA1AC3D-4A61-2996-E050-BB89AD433AFF","latestVersionIndicator":"Yes","beginDate":"2015-08-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-08-31","modifiedBy":"COOPERM","dateModified":"2015-09-28","changeNote":"Created for 1402 study in Rave per request by R.Marasigan. mc 8/31/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4993818","version":"1","preferredName":"Eligibility Criteria Aflibercept or Ramucirumab or Cediranib or Cabozantinib or XL184 Administered Indicator","preferredDefinition":"Indicator of whether or not the patient has received aflibercept, ramucirumab, cediranib, cabozantinib, or XL184.","longName":"4993795v1.0:3506068v1.0","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1EA21410-9771-83A6-E050-BB89AD430860","latestVersionIndicator":"Yes","beginDate":"2015-08-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-08-31","modifiedBy":"COOPERM","dateModified":"2015-09-02","changeNote":"Created for 1402 study in Rave per request by R.Marasigan. mc 8/31/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4993819","version":"1","preferredName":"Eligibility Criteria Prior Bevacizumab Administered Indicator","preferredDefinition":"Indicator of whether or not the patient has previously received bevacizumab.","longName":"4993799v1.0:3506068v1.0","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1EA21410-97A3-83A6-E050-BB89AD430860","latestVersionIndicator":"Yes","beginDate":"2015-08-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-08-31","modifiedBy":"SERIANNJ","dateModified":"2021-04-26","changeNote":"Created for 1402 study in Rave per request by R.Marasigan. mc 8/31/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4993820","version":"1","preferredName":"Eligibility Criteria Bevacizumab Most Recent Treatment Regimen Progression Or Recurrence Indicator","preferredDefinition":"Indicator of whether or not the patient has experienced progression or recurrece while on bevacizumab as the most recent treatment regimen.","longName":"4993802v1.0:3506068v1.0","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1EA1AC3D-4A93-2996-E050-BB89AD433AFF","latestVersionIndicator":"Yes","beginDate":"2015-08-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-08-31","modifiedBy":"COOPERM","dateModified":"2015-09-02","changeNote":"Created for 1402 study in Rave per request by R.Marasigan. mc 8/31/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4993821","version":"1","preferredName":"Eligibility Criteria Active Brain Metastases from Systemic Solid Neoplasm Indicator","preferredDefinition":"Indicator of whether or not the patient has active brain metastases from a systemic solid tumor.","longName":"4993813v1.0:3506068v1.0","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1EA21410-97D9-83A6-E050-BB89AD430860","latestVersionIndicator":"Yes","beginDate":"2015-08-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-08-31","modifiedBy":"COOPERM","dateModified":"2015-09-02","changeNote":"Created for 1402 study in Rave per request by R.Marasigan. mc 8/31/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4993834","version":"1","preferredName":"Corticosteroid Evaluation Period Timepoint Administered Indicator","preferredDefinition":"Indicator of whether or not corticosteroids were being given during the evaluation period.","longName":"CORT_EVAL_ADM_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1EA2D170-43F6-30AF-E050-BB89AD434C1C","latestVersionIndicator":"Yes","beginDate":"2015-08-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-08-31","modifiedBy":"COOPERM","dateModified":"2015-09-02","changeNote":"Created for ABTC-1403 study in Rave per request by R.Marasigan. mc 8/31/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4993835","version":"1","preferredName":"Corticosteroid Evaluation Interval Administered Type","preferredDefinition":"Text term that represents the kind of corticosteroids being given during the evaluation period.","longName":"CORT_EVAL_ADM_TP","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1EA2F730-E974-4D70-E050-BB89AD435A9C","latestVersionIndicator":"Yes","beginDate":"2015-08-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-08-31","modifiedBy":"COOPERM","dateModified":"2015-09-02","changeNote":"Created for ABTC-1403 study in Rave per request by R.Marasigan. mc 8/31/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4993836","version":"2","preferredName":"Corticosteroid Evaluation Interval Administered Dose","preferredDefinition":"Numeric representation for the dose of corticosteroids being given during the evaluation period.","longName":"CORT_EVAL_DOSE","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"797308F8-2732-7975-E053-F662850A1896","latestVersionIndicator":"Yes","beginDate":"2015-08-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-10-30","modifiedBy":"COOPERM","dateModified":"2018-10-30","changeNote":"Created for ABTC-1403 study in Rave per request by R.Marasigan. mc 8/31/15 Versioned to include VD v2.0 10.30.18 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5005031","version":"1","preferredName":"Eligibility Criteria Disease Measured by Contrast Enhanced MRI Within 21 Days Start Treatment Indicator","preferredDefinition":"Indicator to signify whether or not the patient has measurable constrast-enchancing disease by MRI within 21 days of starting treatment.","longName":"5005013v1.0:3506068v1.0","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1F669A0D-7830-DBEB-E050-BB89AD4354E7","latestVersionIndicator":"Yes","beginDate":"2015-09-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-09-10","modifiedBy":"TSESU","dateModified":"2020-08-13","changeNote":"Created for ABTC eligibility checklist for 1401 study per request by J.Zhao. mc 9/10/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5097997","version":"1","preferredName":"Protocol Treatment Arm Maximum Tolerated Dose Schedule Assignment Category","preferredDefinition":"Text term that represents the choice of Arm maximum tolerated dose schedule.","longName":"ARM_MTD_DOSE_SCH_CAT","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"28C7B1DC-1CD7-7913-E050-BB89AD430E52","latestVersionIndicator":"Yes","beginDate":"2016-01-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-01-07","modifiedBy":"COOPERM","dateModified":"2016-01-12","changeNote":"Created for ABTC-1202 study in Rave per request by J.Zhao. mc 1/7/16","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5102520","version":"1","preferredName":"Patient Autoimmune Disease Active or Personal Medical History Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"Indicator of whether the patient has active or recent history of known or suspected autoimmune disease.","longName":"4787253v1.0:3506068v1.0","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"294DEE05-A372-9971-E050-BB89AD4330A2","latestVersionIndicator":"Yes","beginDate":"2016-01-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-01-14","modifiedBy":"TSESU","dateModified":"2023-01-04","changeNote":"Created for 1501 study in Rave per request by R.Marasigan. mc 1/14/2016","administrativeNotes":"2022.11.15 AQT added for ticket request CADSR0001697. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5102531","version":"1","preferredName":"Clinical Trial Eligibility Criteria No Significant Hematologic Renal Hepatic Dysfunction Indicator","preferredDefinition":"Indicator of whether the patient has no evidence of significant hematologic, renal, or hepatic dysfunction.","longName":"5102513v1.0:3506068v1.0","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"294DEE05-A3BE-9971-E050-BB89AD4330A2","latestVersionIndicator":"Yes","beginDate":"2016-01-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-01-14","modifiedBy":"COOPERM","dateModified":"2016-01-26","changeNote":"Created for 1501 study in Rave per request by R.Marasigan. mc 1/14/2016","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5102532","version":"1","preferredName":"Patient Prior Chronic Hepatic History Eligibility Determination Indicator","preferredDefinition":"Indicator of whether the patient has history of any chronic hepatitis as evidenced by the mentioned tests.","longName":"3109924v1.0:3506068v1.0","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"294E421F-2D53-6BDD-E050-BB89AD43531F","latestVersionIndicator":"Yes","beginDate":"2016-01-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-01-14","modifiedBy":"COOPERM","dateModified":"2016-01-26","changeNote":"Created for 1501 study in Rave per request by R.Marasigan. mc 1/14/2016","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5102533","version":"1","preferredName":"Clinical Trial Eligibility Criteria Hepatitis C Virus And Hepatitis B Virus Core Antigen Measurement Negative Test Result Indicator","preferredDefinition":"Indicator of whether the patient is HCV negative (by qPCR) and HBcAb negative (no prior Hepatitis B infection).","longName":"5102519v1.0:3506068v1.0","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"294E421F-2D85-6BDD-E050-BB89AD43531F","latestVersionIndicator":"Yes","beginDate":"2016-01-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-01-14","modifiedBy":"BOWSERC","dateModified":"2021-03-16","changeNote":"Created for 1501 study in Rave per request by R.Marasigan. mc 1/14/2016","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5103863","version":"1","preferredName":"Clinical Trial Eligibility Criteria No Mass Effect Or Midline Shift Evidence Indicator","preferredDefinition":"Indicator of whether the patient has no evidence of mass effect and no midline shift.","longName":"5103861v1.0:3506068v1.0","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"296969C0-DB1C-CF7F-E050-BB89AD431D19","latestVersionIndicator":"Yes","beginDate":"2016-01-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-01-15","modifiedBy":"CARTERS","dateModified":"2021-01-21","changeNote":"Created for 1501 study in Rave per request by R.Marasigan. mc 1/15/2016","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5118674","version":"1","preferredName":"Clinical Trial Eligibility Criteria Prior Therapy Other Than Radiation Chemotherapy or Gliadel Wafer Indicator","preferredDefinition":"Indicator of whether patient has had any prior therapies other than radiation, chemotherapy, and Gliadel wafers.","longName":"PRIOR_THERP_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2AF92A22-8A23-399B-E050-BB89AD432A82","latestVersionIndicator":"Yes","beginDate":"2016-02-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-02-04","modifiedBy":"TSESU","dateModified":"2017-12-18","changeNote":"Created for 1501 study in Rave per request by R.Marasigan. mc 2/4/2016","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5121991","version":"1","preferredName":"Patient Cardiovascular Disorder Clinical Trial Eligibility Criteria Yes No Indicator","preferredDefinition":"Indicator of whether or not the patient has uncontrolled or significant cardiovascular disease.","longName":"CARDIO_DZ_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2B842A82-5D5E-194A-E050-BB89AD435DD3","latestVersionIndicator":"Yes","beginDate":"2016-02-11","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-02-11","modifiedBy":"CLOHNES","dateModified":"2023-09-26","changeNote":"Created for 1501 study in Rave per request by R.Marasigan. mc 2/11/16","administrativeNotes":"9/26/23 Added alt oid,CCTG and AQT for ticket number CADSR0002884 cjl. 2023.8.14 AQT added per ticket request CADSR0002739. ak 12/20/22 added AQT for ticket number CADSR0001818 cjl;","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5189978","version":"1","preferredName":"Clinical Trial Eligibility Criteria Surgical Catheter Successful Placement Indicator","preferredDefinition":"Indicator for whether or not the surgical catheter was placed successfully.","longName":"CATH_PLACE_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2EB8899E-1B0F-D7C8-E050-BB89AD4354F7","latestVersionIndicator":"Yes","beginDate":"2016-03-23","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-03-23","modifiedBy":"COOPERM","dateModified":"2016-03-23","changeNote":"Created for 1202 study in Rave per request by J.Zhao. mc 3/23/16","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5216374","version":"1","preferredName":"Clinical Trial Eligibility Criteria Hepatitis C Antibody Positive Finding Indicator","preferredDefinition":"Indicator of whether or not a patient's HCV antibody test is positive.","longName":"HCV_POS_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"304B7BBF-39D9-43FF-E050-BB89AD430810","latestVersionIndicator":"Yes","beginDate":"2016-04-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-04-12","modifiedBy":"VUJANOVA","dateModified":"2019-08-30","changeNote":"Created for 1501 study in Rave per request by R.Marasigan. mc 4/12/16","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5216375","version":"1","preferredName":"Clinical Trial Eligibility Criteria Hepatitis B Virus Core Antibody Positive Indicator","preferredDefinition":"Indicator of whether or not a patient's HBc antibody test is positive.","longName":"HBC_POS_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"304B7BBF-3A00-43FF-E050-BB89AD430810","latestVersionIndicator":"Yes","beginDate":"2016-04-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-04-12","modifiedBy":"COOPERM","dateModified":"2016-05-18","changeNote":"Created for 1501 study in Rave per request by R.Marasigan. mc 4/12/16","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5222577","version":"1","preferredName":"Clinical Trial Eligibility Criteria Female Patient Childbearing Potential Contraception Agreement Indicator","preferredDefinition":"Indicator of whether or not a patient who is a woman of childbearing potential, has agreed to use contraception.","longName":"FEMALE_CONTRCPT_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3066FFE0-AD5A-3F38-E050-BB89AD4326A1","latestVersionIndicator":"Yes","beginDate":"2016-04-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-04-13","modifiedBy":"TSESU","dateModified":"2019-08-05","changeNote":"Created for ABTC-1501 study in Rave per request by R.Marasigan. mc 4/13/16 03-09-2018 Fix space at end of question text.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5222588","version":"1","preferredName":"Clinical Trial Eligibility Criteria Male Patient Contraception Agreement Indicator","preferredDefinition":"Indicator of whether or not a patient who is a sexually active man of reproductive potential who partners with women of reproductive potential, has agreed to use contraception.","longName":"MALE_CONTRCPT_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3067ABFD-60E3-8B7D-E050-BB89AD433586","latestVersionIndicator":"Yes","beginDate":"2016-04-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-04-13","modifiedBy":"SOKKERL","dateModified":"2022-12-15","changeNote":"Created for ABTC-1501 study in Rave per request by R.Marasigan. mc 4/13/16 03-09-2018 Fix space at end of question text DW","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5260819","version":"1","preferredName":"Person Agent QTcB Prolongation Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"Indicator of whether or not agents which prolong QTc measurements are being received by the patient.","longName":"AGENT_QTCB_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"32AD22F1-1B4C-9B21-E050-BB89AD436BE5","latestVersionIndicator":"Yes","beginDate":"2016-05-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-05-12","modifiedBy":"TSESU","dateModified":"2017-09-18","changeNote":"Created for ABTC 1302 study in Rave which needed NA as a PV. mc 5/12/16","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5326134","version":"1","preferredName":"Laboratory Procedure Direct Bilirubin Collection Date","preferredDefinition":"The date on which a blood sample was collected to measure the amount of direct bilirubin present.","longName":"DIR_BILI_COL_DT","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"364969C2-86B5-51F0-E050-BB89AD436D6B","latestVersionIndicator":"Yes","beginDate":"2016-06-27","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-06-27","modifiedBy":"COOPERM","dateModified":"2016-07-12","changeNote":"Created for 1501 study in Rave. mc 6/27/16","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5342751","version":"1","preferredName":"Prior EGFR Therapy Other Than EGFRvIII Eligibility Criteria Indicator","preferredDefinition":"Indicator of whether or not the patient received prior therapy of an EGFR inhibitor other than EGFRvIII vaccine.","longName":"THER_OTHER_EFGR_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"37730E09-6729-A481-E050-BB89AD431C8E","latestVersionIndicator":"Yes","beginDate":"2016-07-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-07-12","modifiedBy":"COOPERM","dateModified":"2016-07-12","changeNote":"Created for ABTC-1302 study in Rave per request by J.Zhao. mc 7/12/16","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5395171","version":"1","preferredName":"Injection Administered Count","preferredDefinition":"The number of injections given.","longName":"INJ_ADM_CNT","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"39A8D39F-588F-B97C-E050-BB89AD436621","latestVersionIndicator":"Yes","beginDate":"2016-08-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-08-09","modifiedBy":"COOPERM","dateModified":"2016-11-08","changeNote":"Created for ABTC 1403 as requested by J.Zhao. mc 8/9/16","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5455235","version":"1","preferredName":"Prior Molecular Analysis Same Specimen Performed Indicator","preferredDefinition":"Indicator of whether or not prior molecular studies were done on the same specimen.","longName":"PR_MOLC_AN_SMESP_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C01D4E6-BC02-3014-E050-BB89AD4346F6","latestVersionIndicator":"Yes","beginDate":"2016-09-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-09-08","modifiedBy":"COOPERM","dateModified":"2016-11-08","changeNote":"Created for change to 1302 study in Rave as requested by R.Marasigan. mc 9/8/16","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5547836","version":"1","preferredName":"Laboratory Procedure Fasting Glucose Collection Date","preferredDefinition":"The date on which a fasting blood sample was collected to measure the amount of glucose present.","longName":"FAST_GLU_COL_DT","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3FE01564-52F2-62DF-E053-F662850AEBA7","latestVersionIndicator":"Yes","beginDate":"2016-10-27","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-10-27","modifiedBy":"COOPERM","dateModified":"2016-11-08","changeNote":"Created for 1302 study in Rave. mc 6/27/16","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5547863","version":"1","preferredName":"Laboratory Procedure Hemoglobin A1c Collection Date","preferredDefinition":"The date on which a blood sample was collected to measure the amount of glycosylated hemoglobin (HbA1c) present.","longName":"HBA1C_COL_DT","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3FE01564-5355-62DF-E053-F662850AEBA7","latestVersionIndicator":"Yes","beginDate":"2016-10-27","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-10-27","modifiedBy":"MORENOC","dateModified":"2018-02-06","changeNote":"Created for 1302 study in Rave. mc 6/27/16","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5577062","version":"1","preferredName":"Glucose Greater Than or Equal To 150 mg/dL Level Indicator","preferredDefinition":"Indicator of whether or not the glucose level was greater than or equal to 150 mg/dL.","longName":"GLU_GRTNEQTO_150_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"415BA6AD-BA65-0947-E053-F662850A1795","latestVersionIndicator":"Yes","beginDate":"2016-11-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-11-15","modifiedBy":"MORENOC","dateModified":"2018-02-08","changeNote":"Created for 1301 study in Rave. mc 11/15/16","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5577063","version":"1","preferredName":"Glucose Highest Grade","preferredDefinition":"Numeric representation of the highest glucose grade recorded.","longName":"GLU_HIGH_GRADE","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"415BA6AD-BA8C-0947-E053-F662850A1795","latestVersionIndicator":"Yes","beginDate":"2016-11-15","endDate":null,"createdBy":"COOPERM","dateCreated":"2016-11-15","modifiedBy":"COOPERM","dateModified":"2017-02-14","changeNote":"Created for 1301 study in Rave. mc 11/15/16","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5622019","version":"1","preferredName":"Eligibility Criteria Recovery Immediate Postoperative Period Indicator","preferredDefinition":"Indicator of whether or not the patient recovered from the latest surgery.","longName":"POSTOP_RECOVR_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"45B27893-4627-1E17-E053-F662850A1252","latestVersionIndicator":"Yes","beginDate":"2017-01-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-01-09","modifiedBy":"COOPERM","dateModified":"2017-01-20","changeNote":"Created for 1601 study in Rave per request by J.Zhao. mc 1/9/17","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5622020","version":"1","preferredName":"Eligibility Criteria Tumor MGMT Unmethylated Status Indicator","preferredDefinition":"Indicator of whether or not the tumor MGMT methylation status is unmethylated.","longName":"UNMETHYL_STAT_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"45B4AFBA-8C23-61B4-E053-F662850A9588","latestVersionIndicator":"Yes","beginDate":"2017-01-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-01-09","modifiedBy":"COOPERM","dateModified":"2017-01-20","changeNote":"Created for 1601 study in Rave per request by J.Zhao. mc 1/9/17","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5622021","version":"1","preferredName":"Eligibility Criteria Received Prior Therapy for Brain Tumor Indicator","preferredDefinition":"Indicator of whether or not the patient received any kind of prior therapy for their brain tumor.","longName":"PR_THERP_BRAIN_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"45B3EB04-10B7-7C8A-E053-F662850ACDB7","latestVersionIndicator":"Yes","beginDate":"2017-01-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-01-09","modifiedBy":"COOPERM","dateModified":"2017-01-20","changeNote":"Created for 1601 study in Rave per request by J.Zhao. mc 1/9/17","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5622022","version":"1","preferredName":"Eligibility Criteria Agreement No Sperm Donor Indicator","preferredDefinition":"Indicator of whether or not male patients have agreed to not donate sperm.","longName":"NOSPERM_DONOR_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"45B3EB04-10DE-7C8A-E053-F662850ACDB7","latestVersionIndicator":"Yes","beginDate":"2017-01-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-01-09","modifiedBy":"COOPERM","dateModified":"2017-01-20","changeNote":"Created for 1601 study in Rave per request by J.Zhao. mc 1/9/17","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5622023","version":"1","preferredName":"Eligibility Criteria Stable Corticosteroid Regimen Prior to Start of Treatment Indicator","preferredDefinition":"Indicator of whether or not the patient be on a stable corticosteroid regimen prior to the start of treatment.","longName":"STBL_CORTICOS_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"45B4AFBA-8C4A-61B4-E053-F662850A9588","latestVersionIndicator":"Yes","beginDate":"2017-01-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-01-09","modifiedBy":"TSESU","dateModified":"2018-08-02","changeNote":"Created for 1601 study in Rave per request by J.Zhao. mc 1/9/17","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5622024","version":"1","preferredName":"Eligibility Criteria Using Coumarin Anticoagulant Agent Indicator","preferredDefinition":"Indicator of whether or not the patient on coumarin anticoagulant.","longName":"USE_COUMARIN_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"45B3EB04-1105-7C8A-E053-F662850ACDB7","latestVersionIndicator":"Yes","beginDate":"2017-01-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-01-09","modifiedBy":"COOPERM","dateModified":"2017-01-20","changeNote":"Created for 1601 study in Rave per request by J.Zhao. mc 1/9/17","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5622025","version":"1","preferredName":"Eligibility Criteria Acute or Chronic Hepatitis B or C Virus Infection Indicator","preferredDefinition":"Indicator of whether or not the patient has an acute or chronic Hepatitis B or Hepatitis C Virus infection.","longName":"HEPB_HEPC_INF_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"45B3EB04-112C-7C8A-E053-F662850ACDB7","latestVersionIndicator":"Yes","beginDate":"2017-01-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-01-09","modifiedBy":"COOPERM","dateModified":"2017-02-07","changeNote":"Created for 1601 study in Rave per request by J.Zhao. mc 1/9/17","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5622029","version":"1","preferredName":"Eligibility Criteria Hypertension Present Initial Visit Indicator","preferredDefinition":"Indicator of whether or not the patient has systolic blood pressure greater than or equal to 140 mmHg or diastolic blood pressure greater than or equal to 90 mmHg.","longName":"HYPERTENS_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"45B50698-6FCE-1950-E053-F662850AC63F","latestVersionIndicator":"Yes","beginDate":"2017-01-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-01-09","modifiedBy":"COOPERM","dateModified":"2017-01-20","changeNote":"Created for 1601 study in Rave per request by J.Zhao. mc 1/9/17","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5622030","version":"1","preferredName":"Eligibility Criteria Using Combination Antihypertensive Agent Indicator","preferredDefinition":"Indicator of whether or not the patient is being treated with more than two antihypertensive medications.","longName":"COMBO_ANTIHYPER_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"45B50698-6FF5-1950-E053-F662850AC63F","latestVersionIndicator":"Yes","beginDate":"2017-01-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-01-09","modifiedBy":"COOPERM","dateModified":"2017-01-20","changeNote":"Created for 1601 study in Rave per request by J.Zhao. mc 1/9/17","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5622031","version":"1","preferredName":"Eligibility Criteria Sustained Ventricular Tachycardia or Ventricular Fibrillation or Torsades De Pointes History Indicator","preferredDefinition":"Indicator of whether or not the patient has a history of sustained ventricular tachycardia, ventricular fibrillation, or torsades de pointes.","longName":"TACH_FIB_TDP_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"45B3EB04-1153-7C8A-E053-F662850ACDB7","latestVersionIndicator":"Yes","beginDate":"2017-01-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-01-09","modifiedBy":"COOPERM","dateModified":"2017-01-20","changeNote":"Created for 1601 study in Rave per request by J.Zhao. mc 1/9/17","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5622032","version":"1","preferredName":"Eligibility Criteria Bifascicular Block Indicator","preferredDefinition":"Indicator of whether or not the patient had a bifascicular block.","longName":"BIFASCLR_BLK_IN","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"45B3EB04-117A-7C8A-E053-F662850ACDB7","latestVersionIndicator":"Yes","beginDate":"2017-01-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-01-09","modifiedBy":"COOPERM","dateModified":"2017-01-20","changeNote":"Created for 1601 study in Rave per request by J.Zhao. mc 1/9/17","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5622033","version":"1","preferredName":"Eligibility Criteria Myocardial Infarction or Acute Coronary Syndrome or Coronary Revascularization Procedure or Coronary Artery Bypass Surgery Prior to Start Study Drug Indicator","preferredDefinition":"Indicator of whether or not the patient had a myocardial infarction, acute coronary syndrome, coronary revascularization procedures, or coronary arterial bypass grafting prior to starting the study drug.","longName":"HEART_COMP_TRTM_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"45B50698-701C-1950-E053-F662850AC63F","latestVersionIndicator":"Yes","beginDate":"2017-01-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-01-09","modifiedBy":"COOPERM","dateModified":"2017-01-20","changeNote":"Created for 1601 study in Rave per request by J.Zhao. mc 1/9/17","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5622034","version":"1","preferredName":"Eligibility Criteria Ventricular Response Rate Value","preferredDefinition":"Numeric representation of the patient's ventricular response rate.","longName":"VRR_VAL","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"45B50698-7043-1950-E053-F662850AC63F","latestVersionIndicator":"Yes","beginDate":"2017-01-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-01-09","modifiedBy":"COOPERM","dateModified":"2017-01-20","changeNote":"Created for 1601 study in Rave per request by J.Zhao. mc 1/9/17","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5622038","version":"1","preferredName":"Eligibility Criteria Pregnancy Test Agreement Indicator","preferredDefinition":"Indicator of whether or not the patient has agreed to a serum preganancy test.","longName":"PREG_TEST_AGREE_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"45B589D5-3A55-647C-E053-F662850AACAC","latestVersionIndicator":"Yes","beginDate":"2017-01-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-01-09","modifiedBy":"TSESU","dateModified":"2020-02-14","changeNote":"Created for 1601 study in Rave per request by J.Zhao. mc 1/9/17","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5639073","version":"1","preferredName":"Laboratory Procedure Troponin T Value","preferredDefinition":"Numeric representation of the amount of troponin T present in a blood sample.","longName":"LAB_CTNT_VAL","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"475B237C-CB98-7116-E053-F662850A2E62","latestVersionIndicator":"Yes","beginDate":"2017-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-01-30","modifiedBy":"COOPERM","dateModified":"2017-02-14","changeNote":"Created for ABTC 1601 Eligibility Checklist. mc 1/30/17","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5639074","version":"1","preferredName":"Laboratory Procedure Troponin T Upper Limit of Normal Value","preferredDefinition":"Numeric representation of the top value of the range for the determination of the amount of troponin T present in a blood sample.","longName":"LAB_CTNT_ULN_VAL","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"475AA4D5-6DBF-71E2-E053-F662850A961A","latestVersionIndicator":"Yes","beginDate":"2017-01-30","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-01-30","modifiedBy":"COOPERM","dateModified":"2017-02-14","changeNote":"Created for ABTC 1601 Eligibility Checklist. mc 1/30/17","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5655624","version":"1","preferredName":"Laboratory Procedure Troponin Specimen Collection Date","preferredDefinition":"The date on which a blood sample was collected to measure the amount of troponin.","longName":"TROPN_COLL_DT","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"47F822E3-E40D-615F-E053-F662850A468E","latestVersionIndicator":"Yes","beginDate":"2017-02-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-02-07","modifiedBy":"COOPERM","dateModified":"2017-02-08","changeNote":"Created for 1601. mc 2/7/17","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5655634","version":"1","preferredName":"Cardiac Exam Method Type","preferredDefinition":"Text term that represents the kind of examination performed to assess cardiac status.","longName":"CARD_EX_MTHD_TP","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"47F81461-FCB4-551D-E053-F662850A7E86","latestVersionIndicator":"Yes","beginDate":"2017-02-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-02-07","modifiedBy":"COOPERM","dateModified":"2017-02-08","changeNote":"Created for 1601. mc 2/7/17","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5655635","version":"1","preferredName":"Examination History Physical Neurologic Examination Performed Indicator","preferredDefinition":"Indicator of whether or not the history and physical and neurological examinations were performed.","longName":"EX_HIST_PHY_NEUR_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"47F81461-FCDA-551D-E053-F662850A7E86","latestVersionIndicator":"Yes","beginDate":"2017-02-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-02-07","modifiedBy":"COOPERM","dateModified":"2017-02-08","changeNote":"Created for 1601. mc 2/7/17","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5659852","version":"1","preferredName":"Cardiac Condition NYHA Congestive Heart Failure Indicator","preferredDefinition":"Indicator of whether or not a patient has Class III-IV New York Heart Association (NYHA) congestive heart failure.","longName":"CC_NYHA_CHF_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4836B373-3954-5BAE-E053-F662850AB49E","latestVersionIndicator":"Yes","beginDate":"2017-02-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-02-10","modifiedBy":"SHUJIEH","dateModified":"2018-05-16","changeNote":"Created for ABTC 1601. mc 2/10/17","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5659926","version":"1","preferredName":"Gastrointestinal Condition Agent Intolerance or Absorption Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"Indicator of whether or not a patient has any gastrointestinal conditions or prior procedures that might predispose for drug intolerability or poor drug absorption.","longName":"GI_COND_AGNT_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"48366EE8-40F3-5C79-E053-F662850A0CFF","latestVersionIndicator":"Yes","beginDate":"2017-02-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-02-10","modifiedBy":"ZHWENDY","dateModified":"2022-11-08","changeNote":"Created for ABTC 1601. mc 2/10/17","administrativeNotes":"7/12/0222: fixed the special character \"\"Crohns\" in AQTs per#1301.wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5659927","version":"1","preferredName":"Peripheral Neuropathy Moderate Adverse Event Present Indicator","preferredDefinition":"Indicator of whether or not the patient has greater than or equal to grade 2 peripheral neuropathy.","longName":"PRPH_NEUROP_MOD_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"48367B7B-9594-5E29-E053-F662850ACE37","latestVersionIndicator":"Yes","beginDate":"2017-02-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-02-10","modifiedBy":"COOPERM","dateModified":"2017-02-14","changeNote":"Created for ABTC 1601. mc 2/10/17","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5664678","version":"1","preferredName":"Concomitant Agent Evaluation Period Begin Date","preferredDefinition":"The start date of the concomitant medication assessment period.","longName":"CONCM_EVAL_STR_DT","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4883A32D-89B1-6EAB-E053-F662850ABCBD","latestVersionIndicator":"Yes","beginDate":"2017-02-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-02-14","modifiedBy":"COOPERM","dateModified":"2017-03-10","changeNote":"Created for 1601. mc 2/14/17","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5664684","version":"1","preferredName":"Concomitant Agent Evaluation Period End Date","preferredDefinition":"The end date of the concomitant medication assessment period.","longName":"CONCM_EVAL_END_DT","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"488010AF-72C8-42E5-E053-F662850A5200","latestVersionIndicator":"Yes","beginDate":"2017-02-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-02-14","modifiedBy":"COOPERM","dateModified":"2017-03-10","changeNote":"Created for 1601. mc 2/14/17","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5682932","version":"1","preferredName":"MGMT Performed Date","preferredDefinition":"The date on which a methylated-DNA-protein-cysteine methyltransferase (MGMT) test was done.","longName":"MGMT_PERF_DT","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"498AEAE8-6DE7-54B0-E053-F662850AEB8D","latestVersionIndicator":"Yes","beginDate":"2017-02-27","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-02-27","modifiedBy":"COOPERM","dateModified":"2017-02-27","changeNote":"Created for 1601 study in Rave. mc 2/27/17","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5682934","version":"1","preferredName":"Radiation Therapy Planned Dose Value","preferredDefinition":"Numeric representation for the dose of radiation therapy the patient is expected to receive.","longName":"RT_PLND_DOSE_VAL","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"498AF7AD-7DE8-54B4-E053-F662850A5477","latestVersionIndicator":"Yes","beginDate":"2017-02-27","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-02-27","modifiedBy":"GARRIDOJ","dateModified":"2018-09-04","changeNote":"Created for 1601 study in Rave. mc 2/27/17","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5682954","version":"1","preferredName":"MGMT Test Method Type","preferredDefinition":"Text term that represents the kind of test method used to determine MGMT status.","longName":"MGMT_METHOD_TP","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"498B4DAE-2A2B-7561-E053-F662850A0EBD","latestVersionIndicator":"Yes","beginDate":"2017-02-27","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-02-27","modifiedBy":"COOPERM","dateModified":"2017-02-27","changeNote":"Created for 1601 study in Rave. mc 2/27/17","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5698599","version":"1","preferredName":"WHO 2016 Classification of Diffuse Astrocytoma And Oligodendroglial Tumors Name","preferredDefinition":"Text term to represent the name of the 2016 WHO (World Health Organization) classification of a brain tumor.","longName":"WHO_DAST_OLG_TMR_NM","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"WHO:World Health Organization","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A2D81A4-D2D4-63E4-E053-F662850AA42C","latestVersionIndicator":"Yes","beginDate":"2017-03-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-03-07","modifiedBy":"COOPERM","dateModified":"2017-03-10","changeNote":"Created for ABTC-1601 study in Rave. mc 3/7/17","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5698600","version":"1","preferredName":"WHO 2016 Classification of Diffuse Astrocytoma And Oligodendroglial Tumors Code","preferredDefinition":"Numeric code that corresponds to the WHO (World Health Organization) classifications for brain tumors.","longName":"WHO_DAST_OLG_TMR_CD","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"WHO:World Health Organization","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A2D5F7F-FC11-6606-E053-F662850A1590","latestVersionIndicator":"Yes","beginDate":"2017-03-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-03-07","modifiedBy":"COOPERM","dateModified":"2017-03-27","changeNote":"Created for ABTC-1601 study in Rave. mc 3/7/17","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5702329","version":"1","preferredName":"Eligibility Criteria Glioblastoma RANO Criteria Indicator","preferredDefinition":"Indicator of whether or not the patient has histologically confirmed glioblastoma that is progressive or recurrent following treatment according to the Response Assessment in Neuro-Oncology (RANO) criteria.","longName":"ELIG_GLB_RANO_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A550260-65E1-33BC-E053-F662850AC8B1","latestVersionIndicator":"Yes","beginDate":"2017-03-09","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-03-09","modifiedBy":"TSESU","dateModified":"2017-04-03","changeNote":"Created for 1602 study in Rave. mc 3/9/17","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5719441","version":"1","preferredName":"Eligibility Criteria Adverse Event Pre-Existing Indicator","preferredDefinition":"Indicator of whether or not the patient has an unresolved toxicity from previous anti-cancer therapy.","longName":"PRE_EXIST_AE_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4B2F0F67-510C-78A3-E053-F662850AE76A","latestVersionIndicator":"Yes","beginDate":"2017-03-20","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-03-20","modifiedBy":"TSESU","dateModified":"2020-02-26","changeNote":"Created for 1602 study in Rave. mc 3/20/17","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5774019","version":"1","preferredName":"Non-Enhancing Lesion RANO Criteria T2 and FLAIR MRI Change Evaluation Result","preferredDefinition":"Text term to indicate the change status of non-enhancing lesions by Response Assessment in Neuro-Oncology criteria (RANO) measured using T2 and Fluid Attenuated Inversion Recovery MRI.","longName":"NONENH_T2FLAIR_RSLT","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D132939-27CF-3938-E053-F662850A352F","latestVersionIndicator":"Yes","beginDate":"2017-04-13","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-04-13","modifiedBy":"COOPERM","dateModified":"2017-04-17","changeNote":"Created for On Study 1602 CRF request 4Apr. mc 4/13/17","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5832506","version":"1","preferredName":"Person Receive Inhibitor And/Or Inducer Medication Substance Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"The indicator to determine patient eligibility for clinical trial participation as outlined in the protocol for questions related to taking inhibitors or inducers.","longName":"5832505v1.0:3506068v1.0","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4FC1F7CC-5A6B-163E-E053-F662850A4EBA","latestVersionIndicator":"Yes","beginDate":"2017-05-18","endDate":null,"createdBy":"TSESU","dateCreated":"2017-05-18","modifiedBy":"TSESU","dateModified":"2017-05-18","changeNote":"Created for protocol ABTC-1601 per J. Zhao's request. ST 5/17/17.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5985740","version":"1","preferredName":"Female Contraception Agreement Indicator","preferredDefinition":"Indicator of whether the female patient of childbearing potential agrees to use an adequate method of contraception throughout the study.","longName":"CNTCPT_AG_FM_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5ABAB045-5341-258A-E053-F662850AD8F4","latestVersionIndicator":"Yes","beginDate":"2017-10-04","endDate":null,"createdBy":"TSESU","dateCreated":"2017-10-04","modifiedBy":"TSESU","dateModified":"2020-02-14","changeNote":"Created for ABTC 1604: smt 10/5/17","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5985753","version":"1","preferredName":"Eligibility Criteria Therapy Complementary and Alternative Medicine Administered Indicator","preferredDefinition":"Indicator of whether complementary and alternative medicine was administered.","longName":"ELIG_ALTTX_ADM_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5ABABF7F-4E93-259A-E053-F662850ADA6E","latestVersionIndicator":"Yes","beginDate":"2017-10-04","endDate":null,"createdBy":"TSESU","dateCreated":"2017-10-04","modifiedBy":"COOPERM","dateModified":"2018-10-30","changeNote":"Created for ABTC-1604: smt 10/4/17 Revised Short name and revised PQ: smt 11/8/17","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5986029","version":"1","preferredName":"Eligibility Criteria Patient Strong CYP3A CYP2C8 Induction Inhibition Indicator","preferredDefinition":"Indicator of whether the patient is receiving any medications or substances that are strong inhibitors or inducers of cytochrome P450.","longName":"ELIG_P450_INDINH_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5ABAFBDE-474C-1C1C-E053-F662850A3DFD","latestVersionIndicator":"Yes","beginDate":"2017-10-04","endDate":null,"createdBy":"TSESU","dateCreated":"2017-10-04","modifiedBy":"KUMMEROA","dateModified":"2023-03-28","changeNote":"Created for ABTC 1604: smt 10/4/17","administrativeNotes":"2023.3.28 AQT added per ticket request CADSR0002221. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5986030","version":"1","preferredName":"Patient Active Infectious Disorder Systemic Therapy Requirement Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"Indicator of whether the patient has active infection requiring systemic treatment prior to study therapy.","longName":"ACT_INF_DS_SYSTX_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5ABAEBF9-8858-258C-E053-F662850AFE82","latestVersionIndicator":"Yes","beginDate":"2017-10-04","endDate":null,"createdBy":"TSESU","dateCreated":"2017-10-04","modifiedBy":"TSESU","dateModified":"2023-09-28","changeNote":"Created for ABTC 1604: smt 10/4/17","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5986031","version":"1","preferredName":"Prior First Clinical Study Pharmacologic Substance Administration Active Coronary Disease Less Than 6 Month Indicator","preferredDefinition":"Indicator of whether the patient has active coronary disease within 6 months before the start of protocol therapy.","longName":"COR_DZ_LT6MO_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5ABC083E-2971-3C2B-E053-F662850A9D24","latestVersionIndicator":"Yes","beginDate":"2017-10-04","endDate":null,"createdBy":"TSESU","dateCreated":"2017-10-04","modifiedBy":"COOPERM","dateModified":"2018-10-30","changeNote":"Created for ABTC 1604: smt 10/4/17","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5986032","version":"1","preferredName":"Bleeding Diathesis Personal Medical History Clinical Trial Eligibility Criteria Indicator","preferredDefinition":"Indicator of whether the patient has history of bleeding diathesis.","longName":"BLEED_DIATH_HX_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5ABAF480-780B-167E-E053-F662850A3DC6","latestVersionIndicator":"Yes","beginDate":"2017-10-04","endDate":null,"createdBy":"TSESU","dateCreated":"2017-10-04","modifiedBy":"CLOHNES","dateModified":"2022-11-16","changeNote":"Created for ABTC 1604: smt 10/4/17","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5986033","version":"1","preferredName":"Hepatitis B Hepatitis C Infection Personal Medical History Indicator","preferredDefinition":"Indicator of whether the patient has evidence of active Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV).","longName":"HEP_B_C_PMDHX_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5ABC3412-7955-1A45-E053-F662850AA7CE","latestVersionIndicator":"Yes","beginDate":"2017-10-04","endDate":null,"createdBy":"TSESU","dateCreated":"2017-10-04","modifiedBy":"TSESU","dateModified":"2023-09-27","changeNote":"Created for ABTC 1604: smt 10/4/2017","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5989610","version":"1","preferredName":"Eligibility Criteria TP53 wt Allele Evidence Indicator","preferredDefinition":"Indicator of whether patient's disease shows evidence of wild-type (WT) p53 as assessed by central DNA sequencing.","longName":"ELIG_EVID_WTP53_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5AD302E7-55C0-59B6-E053-F662850A40F1","latestVersionIndicator":"Yes","beginDate":"2017-10-05","endDate":null,"createdBy":"TSESU","dateCreated":"2017-10-05","modifiedBy":"ZHWENDY","dateModified":"2022-11-08","changeNote":"Created for ABTC 1604: smt 10/5/17.","administrativeNotes":"7/12/2022: fixed the box symbol \"patients\" in PQT and AQT per ticket #1301.","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5989662","version":"1","preferredName":"Male Contraception Agreement Indicator","preferredDefinition":"Indicator of whether the male patient of fathering potential agrees to use a condom if partner is pregnant or breastfeeding.","longName":"CONTCPT_AGR_MALE_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5AD356FE-5CB0-5AB8-E053-F662850A7DAD","latestVersionIndicator":"Yes","beginDate":"2017-10-05","endDate":null,"createdBy":"TSESU","dateCreated":"2017-10-05","modifiedBy":"COOPERM","dateModified":"2018-10-30","changeNote":"Created for ABTC 1604: smt 10/5/17","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6034877","version":"1","preferredName":"Eligibility HIV Positive With Undetectable HIV Viral Load Receive Highly Active Antiretroviral Therapy Indicator","preferredDefinition":"A response indicating whether or not an HIV-positive patient with undetectable HIV viral load is on a stable regimen of highly active anti-retroviral therapy (HAART).","longName":"HIV_HAART_RCV_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F2863FC-20CA-28E9-E053-F662850A9E1B","latestVersionIndicator":"Yes","beginDate":"2017-11-29","endDate":null,"createdBy":"TSESU","dateCreated":"2017-11-29","modifiedBy":"TSESU","dateModified":"2023-06-06","changeNote":"Created for ABTC-1401 - smt 11/29/17","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6044627","version":"1","preferredName":"Clinical Trial Eligibility Criteria Systemic Immunosuppressive Therapy Requirement Indicator","preferredDefinition":"Indicator of whether or not patient requires systemic immunosuppressive therapy.","longName":"IMMUNO_TX_REQ","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABAS Adult Form:Adaptive Behavior Assessment System, Adult Form. Harrison, P.L., & Oakland, T. The Psychological Corporation, San Antonio, TX, 2003.","workflowStatus":"RELEASED","registrationStatus":"Application","id":"60B649C0-BF32-38C7-E053-F662850A02CA","latestVersionIndicator":"Yes","beginDate":"2017-12-19","endDate":null,"createdBy":"TSESU","dateCreated":"2017-12-19","modifiedBy":"COOPERM","dateModified":"2018-10-30","changeNote":"Created for 1603 - smt 12/19/17","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6044922","version":"1","preferredName":"Clinical Trial Eligibility Criteria Operable Presumed Malignant Glioma Intent Gross Total Resection Indicator","preferredDefinition":"Indicator whether or not patient has presumed high grade glioma that is intended for total surgical resection.","longName":"HGG_RESCTN_INTNT_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"60F03577-F853-180A-E053-F662850AF70D","latestVersionIndicator":"Yes","beginDate":"2017-12-22","endDate":null,"createdBy":"TSESU","dateCreated":"2017-12-22","modifiedBy":"COOPERM","dateModified":"2018-10-30","changeNote":"Created for 1403 study in Rave per request by J.Zhao. mc 8/14/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6199664","version":"1","preferredName":"Buccal Swab Collection Date","preferredDefinition":"Date of buccal swab collection displayed in DDMMMYYYY, with the month display the first three letters of each month (Jan, Feb, Mar, etc.).","longName":"BUCCAL_SWAB_DATE","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"69FA0151-F7CD-2B31-E053-F662850A82BD","latestVersionIndicator":"Yes","beginDate":"2018-04-16","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-16","modifiedBy":"COOPERM","dateModified":"2018-10-30","changeNote":"Created for 1604 - smt 4/16/18","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6199729","version":"1","preferredName":"Buccal Swab Collection Indicator","preferredDefinition":"Indicator of whether or not buccal swab collection was performed.","longName":"BUCCAL_SWAB_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"69FA4A69-7486-70C3-E053-F662850AE8F7","latestVersionIndicator":"Yes","beginDate":"2018-04-16","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-16","modifiedBy":"COOPERM","dateModified":"2018-10-30","changeNote":"Created for 1604 - smt 4/16/18","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6229563","version":"1","preferredName":"Karnofsky Performance Status Score Date","preferredDefinition":"Date Karnofsky Performance Status was performed.","longName":"KPS_PERF_DT","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6A892DAC-18F2-6BC0-E053-F662850AAE5A","latestVersionIndicator":"Yes","beginDate":"2018-04-23","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-23","modifiedBy":"KUMMEROA","dateModified":"2021-07-14","changeNote":"2021-7-6 ak Added context SN.  Created for ABTC-1401 - smt 4/23/18","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6229640","version":"1","preferredName":"Agent Day Administered Day Count","preferredDefinition":"The number of days dosing was administered.","longName":"DOSE_NUM_DAYS","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6A9193E7-93A3-1908-E053-F662850AF14E","latestVersionIndicator":"Yes","beginDate":"2018-04-24","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-24","modifiedBy":"COOPERM","dateModified":"2018-10-30","changeNote":"Created for ABTC-1401 - smt 4/23/18","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6265275","version":"1","preferredName":"Agent Week 1 Dose Modification Type","preferredDefinition":"Dose modification type occurring in week 1.","longName":"DOSE_MOD_WK1_TYPE","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6B5193FF-F204-6BFD-E053-F662850A0F33","latestVersionIndicator":"Yes","beginDate":"2018-05-03","endDate":null,"createdBy":"TSESU","dateCreated":"2018-05-03","modifiedBy":"COOPERM","dateModified":"2018-10-30","changeNote":"Created for ABTC-1603 - smt 5/3/18","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6265280","version":"1","preferredName":"Agent Week 2 Dose Modification Type","preferredDefinition":"Dose modification type occurring in week 2.","longName":"DOSE_MOD_WK2_TYPE","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6B52F9FB-C9B6-60C8-E053-F662850ADDFE","latestVersionIndicator":"Yes","beginDate":"2018-05-03","endDate":null,"createdBy":"TSESU","dateCreated":"2018-05-03","modifiedBy":"COOPERM","dateModified":"2018-10-30","changeNote":"Created for ABTC-1603 - smt 5/3/18","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6298260","version":"1","preferredName":"Baseline Abnormality Common Terminology Criteria for Adverse Events Version 5.0 Term Name","preferredDefinition":"Text that represents the Common Terminology Criteria for Adverse Events low level term name for an adverse event.","longName":"BABN_CTCAE5_NM","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6CCD2AEB-E588-149E-E053-F662850AE297","latestVersionIndicator":"Yes","beginDate":"2018-05-22","endDate":null,"createdBy":"TSESU","dateCreated":"2018-05-22","modifiedBy":"COOPERM","dateModified":"2018-10-30","changeNote":"Created for ABTC 1604 - smt 5/22/18","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6336247","version":"1","preferredName":"Malignant Glioma Histology Confirmation Indicator","preferredDefinition":"Indicator whether or not tumor histology confirmed malignant glioma.","longName":"HSTCNF_MALGLIOMA_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6F04BF84-DFD1-39FE-E053-F662850ACB1F","latestVersionIndicator":"Yes","beginDate":"2018-06-19","endDate":null,"createdBy":"TSESU","dateCreated":"2018-06-19","modifiedBy":"COOPERM","dateModified":"2018-10-30","changeNote":"Created for ABTC-1603 smt 6/19/18","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6336256","version":"2","preferredName":"Transport Condition Type","preferredDefinition":"The type of transport condition.","longName":"TRANSP_COND_TYP","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FB33EEC2-3523-7DA0-E053-731AD00AFA94","latestVersionIndicator":"Yes","beginDate":"2018-06-19","endDate":null,"createdBy":"CLOHNES","dateCreated":"2023-05-08","modifiedBy":"CLOHNES","dateModified":"2023-06-09","changeNote":"Created for ABTC-1603 smt 6/19/18","administrativeNotes":"5/8/23 created this version 2.0 because VD had a minor version change to change min and max length to fit PVs per cleanup activities for ABTC cjl.","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6336260","version":"2","preferredName":"Return Transport Condition Type","preferredDefinition":"The type of return transport condition.","longName":"RET_TRANSP_COND_TYP","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FB340B6B-DBF0-0C34-E053-731AD00AA16B","latestVersionIndicator":"Yes","beginDate":"2018-06-19","endDate":null,"createdBy":"CLOHNES","dateCreated":"2023-05-08","modifiedBy":"CLOHNES","dateModified":"2023-06-09","changeNote":"Created for ABTC-1603 smt 6/19/18","administrativeNotes":"5/8/23 created version 2.0 of CDE due to minor version of VD due to change of min and max length because of cleanup activities for ABTC cjl.","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6336271","version":"1","preferredName":"Vial Removed From Freezer Time","preferredDefinition":"The time at which vial was removed from cold storage (fridge/freezer).","longName":"VIAL_REMOVE_TM","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6F06005F-961F-2E66-E053-F662850A4E2D","latestVersionIndicator":"Yes","beginDate":"2018-06-19","endDate":null,"createdBy":"TSESU","dateCreated":"2018-06-19","modifiedBy":"COOPERM","dateModified":"2018-10-30","changeNote":"Created for ABTC-1603 smt 6/19/18","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6338041","version":"1","preferredName":"Vial Return To Freezer Time","preferredDefinition":"The time at which vial was returned to cold storage (fridge/freezer).","longName":"VIAL_RETURN_TM","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6F20ABBE-E018-0270-E053-F662850AB1A6","latestVersionIndicator":"Yes","beginDate":"2018-06-21","endDate":null,"createdBy":"TSESU","dateCreated":"2018-06-21","modifiedBy":"COOPERM","dateModified":"2018-10-30","changeNote":"Created for ABTC-1603 smt 6/19/18","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6345588","version":"1","preferredName":"Cell Preparation Tube Blood Collection Count","preferredDefinition":"The number of Cell Preparation Tube (CPT) Blood Draw Tubes collected.","longName":"CPT_BLOOD_COLLECT_CT","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"701EABE8-48B3-2195-E053-F662850A753A","latestVersionIndicator":"Yes","beginDate":"2018-07-03","endDate":null,"createdBy":"TSESU","dateCreated":"2018-07-03","modifiedBy":"COOPERM","dateModified":"2018-10-30","changeNote":"Created for ABTC-1603","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6345598","version":"1","preferredName":"Plasma Preparation Tube Blood Collection Count","preferredDefinition":"The number of PPT (Plasma Preparation Tube) Blood Draw Tubes collected.","longName":"PPT_BLOOD_COLLECT_CT","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"701EE5F1-C8AE-66B8-E053-F662850ACF14","latestVersionIndicator":"Yes","beginDate":"2018-07-03","endDate":null,"createdBy":"TSESU","dateCreated":"2018-07-03","modifiedBy":"COOPERM","dateModified":"2018-10-30","changeNote":"Created for ABTC-1603","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6345643","version":"1","preferredName":"Cell Preparation Tube Processing Begin Time","preferredDefinition":"The time at which Cell Preparation Tube (CPT) processing started.","longName":"CPT_PROCESS_START_TM","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"701EABE8-48DA-2195-E053-F662850A753A","latestVersionIndicator":"Yes","beginDate":"2018-07-03","endDate":null,"createdBy":"TSESU","dateCreated":"2018-07-03","modifiedBy":"COOPERM","dateModified":"2018-10-30","changeNote":"Created for ABTC-1603","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6345647","version":"1","preferredName":"Cell Preparation Tube Received Count","preferredDefinition":"The number of Cell Preparation Tube (CPT) tubes received.","longName":"CPT_RECEIVED_CT","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"702015BC-7579-6B3F-E053-F662850A53BF","latestVersionIndicator":"Yes","beginDate":"2018-07-03","endDate":null,"createdBy":"TSESU","dateCreated":"2018-07-03","modifiedBy":"COOPERM","dateModified":"2018-10-30","changeNote":"Created for ABTC-1603","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6345657","version":"1","preferredName":"Cell Preparation Tube Cryovial Aliquot Plasma Collection Count","preferredDefinition":"The number of cryovial aliquots of plasma that resulted from Cell Preparation Tube (CPT) processing.","longName":"CPT_PLAS_COLLECT_CT","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"701F094A-CF69-7130-E053-F662850A68C0","latestVersionIndicator":"Yes","beginDate":"2018-07-03","endDate":null,"createdBy":"TSESU","dateCreated":"2018-07-03","modifiedBy":"COOPERM","dateModified":"2018-10-30","changeNote":"Created for ABTC-1603 smt 7/3/2018","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6345675","version":"1","preferredName":"Cell Preparation Tube Plasma Freezing Time","preferredDefinition":"The time at which Cell Preparation Tube (CPT) Plasma was frozen.","longName":"CPT_PLASMA_FROZEN_TM","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"701EE5F1-C8D7-66B8-E053-F662850ACF14","latestVersionIndicator":"Yes","beginDate":"2018-07-04","endDate":null,"createdBy":"TSESU","dateCreated":"2018-07-04","modifiedBy":"COOPERM","dateModified":"2018-10-30","changeNote":"Created for ABTC-1603 smt 7/3/2018","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6345679","version":"1","preferredName":"Cell Preparation Tube Cryovial Aliquot PBMC Collection Count","preferredDefinition":"The number of cryovial aliquots of Peripheral Blood Mononuclear Cell (PBMC) that resulted from Cell Preparation Tube (CPT) processing.","longName":"CPT_PBMC_COLLECT_CT","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"70275BB7-57AB-1D5A-E053-F662850ADCB9","latestVersionIndicator":"Yes","beginDate":"2018-07-04","endDate":null,"createdBy":"TSESU","dateCreated":"2018-07-04","modifiedBy":"COOPERM","dateModified":"2018-10-30","changeNote":"Created for ABTC-1603 smt 7/3/2018","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6345690","version":"1","preferredName":"Cell Preparation Tube PBMC Freezing Initiation Time","preferredDefinition":"The time at which Cell Preparation Tube (CPT) Peripheral Blood Mononuclear Cell (PBMC) freezing was initiated.","longName":"CPT_PBMC_FRZ_INIT_TM","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"70420F56-8DB2-747E-E053-F662850A6AA6","latestVersionIndicator":"Yes","beginDate":"2018-07-05","endDate":null,"createdBy":"TSESU","dateCreated":"2018-07-05","modifiedBy":"COOPERM","dateModified":"2018-10-30","changeNote":"Created for ABTC-1603 smt 7/5/2018","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6345714","version":"1","preferredName":"PBMC Ultra Low Temperature Freezer To Liquid Nitrogen Storage Transfer Date","preferredDefinition":"The date on which Peripheral Blood Mononuclear Cell (PBMC) was transferred from ultra low temperature to liquid nitrogen storage.","longName":"PBMC_TRNSF_FRZ_LIQNIT_DT","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"70429C65-606D-0ED0-E053-F662850A9E94","latestVersionIndicator":"Yes","beginDate":"2018-07-05","endDate":null,"createdBy":"TSESU","dateCreated":"2018-07-05","modifiedBy":"COOPERM","dateModified":"2018-10-30","changeNote":"Created for ABTC-1603 smt 7/5/2018","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6345718","version":"1","preferredName":"PBMC Ultra Low Temperature Freezer To Liquid Nitrogen Storage Transfer Time","preferredDefinition":"The time at which Peripheral Blood Mononuclear Cell (PBMC) was transferred from ultra low temperature to liquid nitrogen storage.","longName":"PBMC_TRNSF_FRZ_LIQNIT_TM","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7042C943-6A5A-52FF-E053-F662850A893A","latestVersionIndicator":"Yes","beginDate":"2018-07-05","endDate":null,"createdBy":"TSESU","dateCreated":"2018-07-05","modifiedBy":"COOPERM","dateModified":"2018-10-30","changeNote":"Created for ABTC-1603 smt 7/5/2018","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6345733","version":"1","preferredName":"Plasma Preparation Tube Extracellular Vesicle Plasma Processing Begin Time","preferredDefinition":"The time at which Plasma Preparation Tube (PPT) processing of Extracellular Vesicle plasma was started.","longName":"PPT_EV_PRCSS_ST_TM","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7042F62D-EA5B-3301-E053-F662850AA5CA","latestVersionIndicator":"Yes","beginDate":"2018-07-05","endDate":null,"createdBy":"TSESU","dateCreated":"2018-07-05","modifiedBy":"COOPERM","dateModified":"2018-10-30","changeNote":"Created for ABTC-1603 smt 7/5/2018","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6345743","version":"1","preferredName":"Plasma Preparation Tube Receive Count","preferredDefinition":"The number of Plasma Preparation Tube (PPT) received.","longName":"PPT_RECEIVED_CT","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7042C943-6A86-52FF-E053-F662850A893A","latestVersionIndicator":"Yes","beginDate":"2018-07-05","endDate":null,"createdBy":"TSESU","dateCreated":"2018-07-05","modifiedBy":"COOPERM","dateModified":"2018-10-30","changeNote":"Created for ABTC-1603 smt 7/5/2018","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6345764","version":"1","preferredName":"Plasma Preparation Tube Extracellular Vesicle Plasma Freezing Time","preferredDefinition":"The time at which Plasma Preparation Tube (PPT) processed Extracellular Vesicle plasma was frozen.","longName":"PPT_EV_PLASMA_FROZEN_TM","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7043D9DD-3C43-2F95-E053-F662850A614E","latestVersionIndicator":"Yes","beginDate":"2018-07-05","endDate":null,"createdBy":"TSESU","dateCreated":"2018-07-05","modifiedBy":"COOPERM","dateModified":"2018-10-30","changeNote":"Created for ABTC-1603 smt 7/5/2018","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6346006","version":"1","preferredName":"Plasma Preparation Tube Cryovial Aliquot Extracellular Vesicle Plasma Collection Count","preferredDefinition":"The collected number of cryovial aliquots of plasma that resulted from Plasma Preparation Tube (PPT) processing.","longName":"PPT_EV_PLSM_CLCT_CT","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"70464596-52DA-4F72-E053-F662850A5DC7","latestVersionIndicator":"Yes","beginDate":"2018-07-05","endDate":null,"createdBy":"TSESU","dateCreated":"2018-07-05","modifiedBy":"COOPERM","dateModified":"2018-10-30","changeNote":"Created for ABTC-1603 smt 7/5/2018","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6380019","version":"1","preferredName":"Citric Acid Monohydrate Add Time","preferredDefinition":"The time at which citric acid was added to biospecimen tube.","longName":"CITRC_ACID_ADD_TM","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"72452C25-4822-4825-E053-F662850ABA20","latestVersionIndicator":"Yes","beginDate":"2018-07-31","endDate":null,"createdBy":"TSESU","dateCreated":"2018-07-31","modifiedBy":"COOPERM","dateModified":"2018-10-30","changeNote":"Created for ABTC-1601 smt 7/30/18","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6380024","version":"1","preferredName":"Specimen Placement Within Centrifuge Time","preferredDefinition":"The time at which sample was placed in centrifuge.","longName":"SAMPL_IN_CNTRIFGE_TM","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"72456F1F-8468-6CE7-E053-F662850A25D2","latestVersionIndicator":"Yes","beginDate":"2018-07-31","endDate":null,"createdBy":"TSESU","dateCreated":"2018-07-31","modifiedBy":"COOPERM","dateModified":"2018-10-30","changeNote":"Created for ABTC-1601 smt 7/30/18","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6422554","version":"1","preferredName":"Eligibility Criteria Personal Medical History Ischemic Myocardium Indicator","preferredDefinition":"Indicator of whether or not patient has history of ischemic cardiac event including Myocardial infarction.","longName":"HIST_ISCHEMIC_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"749467E8-8485-588C-E053-F662850AC905","latestVersionIndicator":"Yes","beginDate":"2018-08-29","endDate":null,"createdBy":"TSESU","dateCreated":"2018-08-29","modifiedBy":"TSESU","dateModified":"2019-08-28","changeNote":"Created for ABTC 1701 - smt 8/29/18","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6422719","version":"1","preferredName":"Eligibility Criteria Personal Medical History Bradycardia Indicator","preferredDefinition":"Indicator whether or nor patient has a medical history of bradycardia or its symptoms.","longName":"HIST_BRADYCARD_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"74968501-8399-5471-E053-F662850A62CB","latestVersionIndicator":"Yes","beginDate":"2018-08-29","endDate":null,"createdBy":"TSESU","dateCreated":"2018-08-29","modifiedBy":"TSESU","dateModified":"2019-08-28","changeNote":"Created for ABTC 1701 - smt 8/29/18","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6422732","version":"1","preferredName":"Eligibility Criteria Torsades De Pointes Causing Pharmacologic Substance Indicator","preferredDefinition":"Indicator of whether or not patient is currently taking agent know to cause Torsade de Points.","longName":"AGENT_TORSADE_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"74964F58-0789-2301-E053-F662850A8D12","latestVersionIndicator":"Yes","beginDate":"2018-08-29","endDate":null,"createdBy":"TSESU","dateCreated":"2018-08-29","modifiedBy":"COOPERM","dateModified":"2018-10-30","changeNote":"Created for ABTC 1701 - smt 8/29/18","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6430413","version":"1","preferredName":"cDNA Status Text","preferredDefinition":"Text describing cDNA status.","longName":"cDNA_STATUS_TXT","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"75DC310D-DB0F-7763-E053-F662850AC8D0","latestVersionIndicator":"Yes","beginDate":"2018-09-14","endDate":null,"createdBy":"TSESU","dateCreated":"2018-09-14","modifiedBy":"NIKITAP","dateModified":"2022-02-23","changeNote":"Created for 1604 - smt 9/14/18","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6430414","version":"1","preferredName":"Prediction Change Protein Outcome Text","preferredDefinition":"Text describing the predicted protein change.","longName":"PRED_PROT_CHNG_TXT","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"75D5E7EC-3EFB-0FEF-E053-F662850AC154","latestVersionIndicator":"Yes","beginDate":"2018-09-14","endDate":null,"createdBy":"TSESU","dateCreated":"2018-09-14","modifiedBy":"COOPERM","dateModified":"2018-10-30","changeNote":"Created for 1604 - smt 9/14/18","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6430416","version":"1","preferredName":"Tumor Variant Allele Frequency (VAF) Text","preferredDefinition":"Text describing tumor variant allele frequency (VAF).","longName":"TUMOR_VAF_TXT","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"75DC65D7-F218-0DF7-E053-F662850A8059","latestVersionIndicator":"Yes","beginDate":"2018-09-14","endDate":null,"createdBy":"TSESU","dateCreated":"2018-09-14","modifiedBy":"SOKKERL","dateModified":"2019-10-01","changeNote":"Created for 1604 - smt 9/14/18","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6430417","version":"1","preferredName":"Gene Mutant Read Depth Text","preferredDefinition":"Text describing the read depth of mutation.","longName":"TUMOR_COVER_TXT","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"75DC5675-F822-742A-E053-F662850A37A8","latestVersionIndicator":"Yes","beginDate":"2018-09-14","endDate":null,"createdBy":"TSESU","dateCreated":"2018-09-14","modifiedBy":"COOPERM","dateModified":"2018-10-30","changeNote":"Created for 1604 - smt 9/14/18","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6430418","version":"1","preferredName":"Wild Type Read Depth Text","preferredDefinition":"Text describing read depth of non-mutation.","longName":"NORMAL_COVER_TXT","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"75DC8632-8257-4854-E053-F662850AC6F7","latestVersionIndicator":"Yes","beginDate":"2018-09-14","endDate":null,"createdBy":"TSESU","dateCreated":"2018-09-14","modifiedBy":"COOPERM","dateModified":"2018-10-30","changeNote":"Created for 1604 - smt 9/14/18","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6430419","version":"1","preferredName":"Mutation Present Detection Outcome","preferredDefinition":"Outcome of whether sample contains a mutation.","longName":"MUTATION_DETEC_OUTCM","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"75DCA9FB-8580-01DE-E053-F662850A4896","latestVersionIndicator":"Yes","beginDate":"2018-09-14","endDate":null,"createdBy":"TSESU","dateCreated":"2018-09-14","modifiedBy":"COOPERM","dateModified":"2018-10-30","changeNote":"Created for 1604 - smt 9/14/18","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6435315","version":"1","preferredName":"Tissue Sample Normal Control Extracted DNA Source Text","preferredDefinition":"Text to describe the normal control sample used for DNA extraction.","longName":"DNA_NORM_CONTROL_TXT","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"763F2229-7815-11EC-E053-F662850AC2AD","latestVersionIndicator":"Yes","beginDate":"2018-09-19","endDate":null,"createdBy":"TSESU","dateCreated":"2018-09-19","modifiedBy":"COOPERM","dateModified":"2018-10-30","changeNote":"Created for ABTC 1604 - smt 9/19/18","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6641344","version":"1","preferredName":"Enrollment Patient Other Clinical Study Indicator","preferredDefinition":"Indicator of whether the patient will be enrolled into other portions of the primary study.","longName":"PT_OTH_ENROLLM_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"81B73539-619A-65BA-E053-F662850A7762","latestVersionIndicator":"Yes","beginDate":"2019-02-12","endDate":null,"createdBy":"TSESU","dateCreated":"2019-02-12","modifiedBy":"TSESU","dateModified":"2022-07-07","changeNote":"Created for ABTC 1501.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6650489","version":"1","preferredName":"Eligibility Criteria Corrected Prolonged QT Interval by ECG Finding Second Assessment Value","preferredDefinition":"The numerical value of the second QTc assessment for study eligibility.","longName":"QTC_ASSESS_2_VAL","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"824487A7-6149-7483-E053-F662850A2DBC","latestVersionIndicator":"Yes","beginDate":"2019-02-19","endDate":null,"createdBy":"TSESU","dateCreated":"2019-02-19","modifiedBy":"TSESU","dateModified":"2022-07-07","changeNote":"Created for ABTC 1604 Eligiblity","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6650882","version":"1","preferredName":"Eligibility Criteria Corrected Prolonged QT Interval by ECG Finding First Assessment Value","preferredDefinition":"The numerical value of the first QTc assessment for study eligibility.","longName":"QTC_ASSESS_1_VAL","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8247DB15-21EB-18F0-E053-F662850A9D09","latestVersionIndicator":"Yes","beginDate":"2019-02-19","endDate":null,"createdBy":"TSESU","dateCreated":"2019-02-19","modifiedBy":"TSESU","dateModified":"2022-07-07","changeNote":"Created for ABTC 1604 Eligiblity","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6650883","version":"1","preferredName":"Eligibility Criteria Corrected Prolonged QT Interval by ECG Finding Third Assessment Value","preferredDefinition":"The numerical value of the third QTc assessment for study eligibility.","longName":"QTC_ASSESS_3_VAL","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8247E32D-19C1-1A66-E053-F662850A4419","latestVersionIndicator":"Yes","beginDate":"2019-02-19","endDate":null,"createdBy":"TSESU","dateCreated":"2019-02-19","modifiedBy":"TSESU","dateModified":"2022-07-07","changeNote":"Created for ABTC 1604 Eligiblity","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6651822","version":"1","preferredName":"Specimen Collection Begin Date","preferredDefinition":"The sample collection begin date.","longName":"COLLECT_BEGIN_DT","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8255221A-9054-3C06-E053-F662850A96A8","latestVersionIndicator":"Yes","beginDate":"2019-02-20","endDate":null,"createdBy":"TSESU","dateCreated":"2019-02-20","modifiedBy":"TSESU","dateModified":"2022-07-07","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6651823","version":"1","preferredName":"Specimen Collection End Date","preferredDefinition":"The sample collection end date.","longName":"COLLECT_END_DT","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8254C51F-F5BB-6114-E053-F662850A1194","latestVersionIndicator":"Yes","beginDate":"2019-02-20","endDate":null,"createdBy":"TSESU","dateCreated":"2019-02-20","modifiedBy":"TSESU","dateModified":"2022-07-07","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6665050","version":"1","preferredName":"Anti-Drug Antibody Detection Status","preferredDefinition":"Information related to the status of whether anti-drug antibodies were detected.","longName":"ADA_DETECT_STA","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"83D499C8-AD7E-2C45-E053-F662850A1BC6","latestVersionIndicator":"Yes","beginDate":"2019-03-11","endDate":null,"createdBy":"TSESU","dateCreated":"2019-03-11","modifiedBy":"CLOHNES","dateModified":"2023-06-09","changeNote":"Created for ABTC-1403 - smt 3/11/2019","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6665051","version":"1","preferredName":"Anti-Drug Antibody Confirmation Status","preferredDefinition":"Text term to describe the status of whether anti-drug antibodies were confirmed.","longName":"ADA_CONFIRM_STA","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"83D499C8-ADA6-2C45-E053-F662850A1BC6","latestVersionIndicator":"Yes","beginDate":"2019-03-11","endDate":null,"createdBy":"TSESU","dateCreated":"2019-03-11","modifiedBy":"CLOHNES","dateModified":"2023-06-09","changeNote":"Created for ABTC 1403 - smt 3/11/2019","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6665052","version":"1","preferredName":"Neutralizing Anti-Drug Antibody Detection Status","preferredDefinition":"Text term to describe the status of whether neutralizing anti-drug antibodies were detected.","longName":"NADA_DETECT_STA","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"83D43FF4-822A-7A9C-E053-F662850A4498","latestVersionIndicator":"Yes","beginDate":"2019-03-11","endDate":null,"createdBy":"TSESU","dateCreated":"2019-03-11","modifiedBy":"CLOHNES","dateModified":"2023-06-09","changeNote":"Created for ABTC-1403 - smt 3/11/2019","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6665055","version":"1","preferredName":"Anti-Drug Antibody Titer Obtained Number","preferredDefinition":"Number representing the amount of titer obtained.","longName":"ADA_TITER_NUM","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"83D4EAF7-CE4D-7AA2-E053-F662850ADDC3","latestVersionIndicator":"Yes","beginDate":"2019-03-11","endDate":null,"createdBy":"TSESU","dateCreated":"2019-03-11","modifiedBy":"TSESU","dateModified":"2022-07-07","changeNote":"Created for ABTC-1403 - smt 3/11/2019","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6685619","version":"1","preferredName":"Phase I Patient Eligibility Criteria Progressive Or Recurrent Glioma Indicator","preferredDefinition":"The response that indicates whether or not the Phase 1 trial patient has confirmed progressive or recurrent glioma.","longName":"ELIGP1_PRG_RECUR_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8593B7A4-89F3-631D-E053-F662850AFE65","latestVersionIndicator":"Yes","beginDate":"2019-04-02","endDate":null,"createdBy":"TSESU","dateCreated":"2019-04-02","modifiedBy":"TSESU","dateModified":"2022-07-07","changeNote":"4/2/19 smt created for ABTC 1801","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6685620","version":"1","preferredName":"Phase II Patient Eligibility Criteria Progressive Or Recurrent Glioma Indicator","preferredDefinition":"The response that indicates whether or not a Phase II trial patient has confirmed progressive or recurrent glioma.","longName":"ELIGP2_PRG_RECUR_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8591E405-4767-41B7-E053-F662850A6054","latestVersionIndicator":"Yes","beginDate":"2019-04-02","endDate":null,"createdBy":"TSESU","dateCreated":"2019-04-02","modifiedBy":"TSESU","dateModified":"2022-07-07","changeNote":"4/2/19 smt created for ABTC 1801","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6685622","version":"1","preferredName":"Eligibility Criteria Post Radiation Therapy Enhance Imaging Technique Viable Neoplasm Indicator","preferredDefinition":"Indicator of whether patient has viable neoplasm post radiation therapy.","longName":"ELIG_VIA_TUMOR_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8593F723-E2AD-6311-E053-F662850A87E3","latestVersionIndicator":"Yes","beginDate":"2019-04-02","endDate":null,"createdBy":"TSESU","dateCreated":"2019-04-02","modifiedBy":"TSESU","dateModified":"2022-07-07","changeNote":"4/2/19 smt created for ABTC 1801 3/6/20 smt revised Preferred question text to reflect deletion of \"Phase II\" from the concept per N. Danda request.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6685623","version":"1","preferredName":"Phase II Patient Eligibility Criteria TMZ And Alkylating Agent Failure Indicator","preferredDefinition":"The response that indicates whether or not the Phase II trial patient has failed Temozolomide (TMZ) and alkylating agent.","longName":"ELIGP2_FAIL_TMZ_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8593B7A4-8A1B-631D-E053-F662850AFE65","latestVersionIndicator":"Yes","beginDate":"2019-04-02","endDate":null,"createdBy":"TSESU","dateCreated":"2019-04-02","modifiedBy":"TSESU","dateModified":"2022-07-07","changeNote":"4/2/19 smt created for ABTC 1801","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6685624","version":"1","preferredName":"Phase II Patient Eligibility Criteria Greater Than Twelve Month Post Therapy Progressive Disease Indicator","preferredDefinition":"The response that indicates whether or not the Phase II trial patient meets the eligibility requirements for participation in a clinical trial time since last therapy has been greater than 12 months.","longName":"ELIGP2_PROGONEYR_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"85945148-8665-0E01-E053-F662850A8BD7","latestVersionIndicator":"Yes","beginDate":"2019-04-02","endDate":null,"createdBy":"TSESU","dateCreated":"2019-04-02","modifiedBy":"TSESU","dateModified":"2022-07-07","changeNote":"4/2/19 smt created for ABTC 1801","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6685625","version":"1","preferredName":"Phase II Patient Eligibility Criteria Post Radiation Therapy Chemotherapy Glioblastoma Diagnosis Indicator","preferredDefinition":"The response that indicates whether or not the Phase II trial patient was diagnosed with glioblastoma following radiotherapy and chemotherapy.","longName":"ELIGP2_G4_PT_RAD_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"85946C1F-58F7-1242-E053-F662850A7177","latestVersionIndicator":"Yes","beginDate":"2019-04-02","endDate":null,"createdBy":"TSESU","dateCreated":"2019-04-02","modifiedBy":"TSESU","dateModified":"2022-07-07","changeNote":"4/2/19 smt created for ABTC 1801","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6685626","version":"1","preferredName":"Surgical Glioma Patient Eligibility Criteria Progressive Or Recurrent Post Therapy And Repeat Surgical Procedure Indicator","preferredDefinition":"The response that indicates whether or not a surgical patient with progressive or recurrent disease post therapy will undergo repeat surgical procedure.","longName":"ELIG_GLIO_SURG_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"859483EB-3C40-161A-E053-F662850AD20E","latestVersionIndicator":"Yes","beginDate":"2019-04-02","endDate":null,"createdBy":"TSESU","dateCreated":"2019-04-02","modifiedBy":"TSESU","dateModified":"2022-07-07","changeNote":"4/2/19 smt created for ABTC 1801","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6685839","version":"1","preferredName":"Phase I Or Phase II Patient Eligibility Criteria Prior Magnetic Resonance Imaging Indicator","preferredDefinition":"The response that indicates whether or not a Phase I or Phase II surgical patient had prior scans.","longName":"ELIG_PRIOR_SCANS_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"85A20E84-52F2-6C14-E053-F662850AA122","latestVersionIndicator":"Yes","beginDate":"2019-04-03","endDate":null,"createdBy":"TSESU","dateCreated":"2019-04-03","modifiedBy":"TSESU","dateModified":"2022-07-07","changeNote":"4/3/19 smt created for ABTC 1801","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6686106","version":"1","preferredName":"Eligibility Criteria Measurable Disease Indicator","preferredDefinition":"The response that indicates whether or not the patient has measurable disease.","longName":"ELIG_MEAS_DIS_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"85A2C392-F6EE-5155-E053-F662850A4F29","latestVersionIndicator":"Yes","beginDate":"2019-04-03","endDate":null,"createdBy":"TSESU","dateCreated":"2019-04-03","modifiedBy":"TSESU","dateModified":"2022-07-07","changeNote":"4/3/19 smt created for ABTC 1801","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6686107","version":"1","preferredName":"Eligibility Criteria 1p 19q Positive Finding Status Indicator","preferredDefinition":"The response that indicates whether or not the patient has 1p/19q positive status.","longName":"ELIG_1P_19Q_STAT_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"85A367FA-C1E3-5E12-E053-F662850A341F","latestVersionIndicator":"Yes","beginDate":"2019-04-03","endDate":null,"createdBy":"TSESU","dateCreated":"2019-04-03","modifiedBy":"TSESU","dateModified":"2022-07-07","changeNote":"4/3/19 smt created for ABTC 1801","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6686108","version":"1","preferredName":"Eligibility Criteria Prior Mutant IDH1/IDH2 Inhibitor Therapeutic Procedure Indicator","preferredDefinition":"The response that indicates whether or not the patient has been previously treated with mutant IDH1/2 proteins.","longName":"ELIG_IDH1_2_TX_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"85A378B1-755F-4A67-E053-F662850A654A","latestVersionIndicator":"Yes","beginDate":"2019-04-03","endDate":null,"createdBy":"TSESU","dateCreated":"2019-04-03","modifiedBy":"SPRINGERL","dateModified":"2019-12-11","changeNote":"4/3/19 smt created for ABTC 1801","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6686109","version":"1","preferredName":"Eligibility Criteria Temozolomide Hypersensitivity Diagnosis Indicator","preferredDefinition":"The response that indicates whether or not the patient has hypersensitivity to Temozolomide (TMZ).","longName":"ELIG_TMZ_SENS_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"85A383DB-8F54-4F56-E053-F662850A341A","latestVersionIndicator":"Yes","beginDate":"2019-04-03","endDate":null,"createdBy":"TSESU","dateCreated":"2019-04-03","modifiedBy":"TSESU","dateModified":"2022-07-07","changeNote":"4/3/19 smt created for ABTC 1801","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6770005","version":"1","preferredName":"Clinical Trial Eligibility Criteria Mutant IDH1 Gene IDH2 Gene Fulfill Study Protocol Specification Indicator","preferredDefinition":"The response that indicates whether or not the patient has IDH mutation types which meet protocol specifications.","longName":"ELIG_IDH1_2_SPEC_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"89A9191D-A9AE-55FD-E053-F662850A9D53","latestVersionIndicator":"Yes","beginDate":"2019-05-24","endDate":null,"createdBy":"TSESU","dateCreated":"2019-05-24","modifiedBy":"TSESU","dateModified":"2022-07-07","changeNote":"5/24/19 smt created for ABTC 1801.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6780857","version":"1","preferredName":"Clinical Trial Eligibility Criteria Lactose Intolerance Confirmation Yes No Indicator","preferredDefinition":"Indicator of whether or not a patient has lactose intolerance.","longName":"LACT_INTOL_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8B379DF4-6D8B-5678-E053-F662850A6A03","latestVersionIndicator":"Yes","beginDate":"2019-06-13","endDate":null,"createdBy":"TSESU","dateCreated":"2019-06-13","modifiedBy":"TSESU","dateModified":"2022-07-07","changeNote":"6/13/19 - smt created for ABTC 1701","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6780859","version":"1","preferredName":"Clinical Trial Eligibility Criteria Within Seven Day Clinical Study Receive Therapeutic Procedure Yes No Indicator","preferredDefinition":"Indicator of whether or not patient had specified treatment(s) within 7 days of start of clinical trial.","longName":"TX_WTHN_SVNDAYS_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8B36BC6F-7F5D-3A39-E053-F662850AC4C5","latestVersionIndicator":"Yes","beginDate":"2019-06-13","endDate":null,"createdBy":"TSESU","dateCreated":"2019-06-13","modifiedBy":"TSESU","dateModified":"2022-07-07","changeNote":"6/13/19 - smt created for ABTC 1701","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6842050","version":"1","preferredName":"Aglatimagene Besadenovec Injection Administered Date","preferredDefinition":"The date of Adv-tK injection.","longName":"ADV_TK_INJECT_DT","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F130096-434C-3D07-E053-F662850AD1B2","latestVersionIndicator":"Yes","beginDate":"2019-08-01","endDate":null,"createdBy":"TSESU","dateCreated":"2019-08-01","modifiedBy":"TSESU","dateModified":"2022-07-07","changeNote":"8/1/19 - smt Created for ABTC 1603","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6842065","version":"1","preferredName":"Valacyclovir Last Dose Administered Date","preferredDefinition":"The last dose date of Valacyclovir administered to patient.","longName":"VALA_LST_DSE_DT","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F13631A-B8E9-370B-E053-F662850AFECB","latestVersionIndicator":"Yes","beginDate":"2019-08-01","endDate":null,"createdBy":"TSESU","dateCreated":"2019-08-01","modifiedBy":"TSESU","dateModified":"2022-07-07","changeNote":"8/1/19 - smt Created for ABTC 1603","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6842066","version":"1","preferredName":"Temozolomide Last Dose Administered Date","preferredDefinition":"The last dose date that Temozolomide was administered to patient.","longName":"TMZ_LAST_DSE_DT","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F12CE32-9A93-31FD-E053-F662850ACAAF","latestVersionIndicator":"Yes","beginDate":"2019-08-01","endDate":null,"createdBy":"TSESU","dateCreated":"2019-08-01","modifiedBy":"TSESU","dateModified":"2022-07-07","changeNote":"8/1/19 - smt Created for ABTC 1603","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6842067","version":"1","preferredName":"Temozolomide Total Cycle Administered Count","preferredDefinition":"The total number of cycles of Temozolomide administered to patient.","longName":"TMZ_CYCL_TOTAL_CT","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F121B58-8DCA-12A8-E053-F662850AA156","latestVersionIndicator":"Yes","beginDate":"2019-08-01","endDate":null,"createdBy":"TSESU","dateCreated":"2019-08-01","modifiedBy":"TSESU","dateModified":"2022-07-07","changeNote":"8/1/19 - smt Created for ABTC 1603","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6842068","version":"1","preferredName":"Nivolumab Total Infusion Administered Count","preferredDefinition":"The total number of Nivolumab infusions administered to the patient.","longName":"NIVO_INFSN_TOTAL_CT","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F134498-C7F3-44A6-E053-F662850A6F70","latestVersionIndicator":"Yes","beginDate":"2019-08-01","endDate":null,"createdBy":"TSESU","dateCreated":"2019-08-01","modifiedBy":"TSESU","dateModified":"2022-07-07","changeNote":"8/1/19 - smt Created for ABTC 1603","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6842072","version":"1","preferredName":"Nivolumab Last Dose Administered Date","preferredDefinition":"The last dose date that Nivolumab was administered to the patient.","longName":"NIVO_LAST_DSE_DT","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F13FD7F-300C-120A-E053-F662850ACB2F","latestVersionIndicator":"Yes","beginDate":"2019-08-01","endDate":null,"createdBy":"TSESU","dateCreated":"2019-08-01","modifiedBy":"TSESU","dateModified":"2022-07-07","changeNote":"8/1/19 - smt Created for ABTC 1603","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6846483","version":"1","preferredName":"Eligibility Criteria Histologic High Grade Glioma Indicator","preferredDefinition":"Indicator for whether or not patient has histologic high grade glioma.","longName":"ELIG_HG_GLIOMA_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F657B91-715E-599B-E053-F662850A37FE","latestVersionIndicator":"Yes","beginDate":"2019-08-05","endDate":null,"createdBy":"TSESU","dateCreated":"2019-08-05","modifiedBy":"TSESU","dateModified":"2022-07-07","changeNote":"8/5/19 smt created for ABTC 1802","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6846493","version":"1","preferredName":"Eligibility Criteria CLIA Laboratory Documented BRAF V600 Mutation Indicator","preferredDefinition":"Indicator for whether or not patient has documented BRAF-V600 mutation by CLIA approved laboratory.","longName":"ELIG_BRAF_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F665830-F85B-4EC8-E053-F662850A6F7E","latestVersionIndicator":"Yes","beginDate":"2019-08-05","endDate":null,"createdBy":"TSESU","dateCreated":"2019-08-05","modifiedBy":"TSESU","dateModified":"2022-07-07","changeNote":"8/5/19 smt created for ABTC 1802","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6846637","version":"1","preferredName":"Eligibility Criteria Restriction Medication Use Indicator","preferredDefinition":"Indicator for whether or not patient used or is using restricted medication.","longName":"ELIG_RESTRCT_RX_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F628214-C10A-143A-E053-F662850A0EE7","latestVersionIndicator":"Yes","beginDate":"2019-08-05","endDate":null,"createdBy":"TSESU","dateCreated":"2019-08-05","modifiedBy":"TSESU","dateModified":"2022-07-07","changeNote":"8/5/19 smt created for ABTC 1802","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6846822","version":"1","preferredName":"Eligibility Criteria Acute Coronary Syndrome Personal Medical History Indicator","preferredDefinition":"Indicator for whether or not patient has history of acute coronary syndromes.","longName":"ELIG_CRNRY_SYNDR_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F64476A-7C50-5958-E053-F662850AC760","latestVersionIndicator":"Yes","beginDate":"2019-08-05","endDate":null,"createdBy":"TSESU","dateCreated":"2019-08-05","modifiedBy":"TSESU","dateModified":"2022-07-07","changeNote":"8/5/19 smt created for ABTC 1802","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6846831","version":"1","preferredName":"Eligibility Criteria Cerebrovascular Accident Or Thromboembolism Personal Medical History Indicator","preferredDefinition":"Indicator for whether or not patient has history of cerebrovascular accident or thromboembolism.","longName":"ELIG_CEREB_THRMB_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F61F1CE-3DE8-4364-E053-F662850A15B6","latestVersionIndicator":"Yes","beginDate":"2019-08-05","endDate":null,"createdBy":"TSESU","dateCreated":"2019-08-05","modifiedBy":"TSESU","dateModified":"2022-07-07","changeNote":"8/5/19 smt created for ABTC 1802","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6847057","version":"1","preferredName":"Eligibility Criteria BRAF Gene Inhibition Or MEK Inhibitor Prior Medication Usage Receive Indicator","preferredDefinition":"Indicator for whether or not patient received prior BRAF or MEK inhibitors.","longName":"ELIG_BRAF_MEK_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F6B9F25-7690-5179-E053-F662850A1342","latestVersionIndicator":"Yes","beginDate":"2019-08-05","endDate":null,"createdBy":"TSESU","dateCreated":"2019-08-05","modifiedBy":"TSESU","dateModified":"2022-07-07","changeNote":"8/5/19 smt created for ABTC 1802","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6847058","version":"1","preferredName":"Eligibility Criteria Activating RAS Mutation Neoplasm Indicator","preferredDefinition":"Indicator for whether or not patient has tumor with RAS activating mutation.","longName":"ELIG_RAS_MUT_TUM_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F6BB037-3D0E-5175-E053-F662850A9CC6","latestVersionIndicator":"Yes","beginDate":"2019-08-05","endDate":null,"createdBy":"TSESU","dateCreated":"2019-08-05","modifiedBy":"TSESU","dateModified":"2022-07-07","changeNote":"8/5/19 smt created for ABTC 1802","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6847059","version":"1","preferredName":"Eligibility Criteria Biospecimen Collection Medical Contraindication Indicator","preferredDefinition":"Indicator for whether or not patient has a contraindication for biospecimen collection.","longName":"ELIG_SPEC_CLLCT_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F6BB037-3D36-5175-E053-F662850A9CC6","latestVersionIndicator":"Yes","beginDate":"2019-08-05","endDate":null,"createdBy":"TSESU","dateCreated":"2019-08-05","modifiedBy":"TSESU","dateModified":"2022-07-07","changeNote":"8/5/19 smt created for ABTC 1802","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6847542","version":"1","preferredName":"Eligibility Criteria Disease or Disorder Personal Medical History Indicator","preferredDefinition":"Indicator for whether or not patient had history of specific diseases or disorders.","longName":"ELIG_DISRDR_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8F7562FD-869C-4B08-E053-F662850A32DA","latestVersionIndicator":"Yes","beginDate":"2019-08-06","endDate":null,"createdBy":"TSESU","dateCreated":"2019-08-06","modifiedBy":"TSESU","dateModified":"2022-07-07","changeNote":"8/5/19 smt created for ABTC 1802","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6867021","version":"1","preferredName":"Eligibility Criteria Personal Medical History Valvular Stenosis Indicator","preferredDefinition":"Indicator of whether or not patient has medical history of valvular stenosis disease.","longName":"STEN_VALV_DIS_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9130BEAB-3C55-7C99-E053-F662850AB695","latestVersionIndicator":"Yes","beginDate":"2019-08-28","endDate":null,"createdBy":"TSESU","dateCreated":"2019-08-28","modifiedBy":"TSESU","dateModified":"2022-07-07","changeNote":"8/28/19 - smt created for ABTC 1804","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6867034","version":"1","preferredName":"Eligibility Criteria Uncontrolled Blood Pressure Indicator","preferredDefinition":"Indicator of whether patient has uncontrolled blood pressure.","longName":"UNCNTRL_BLPRSSRE_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"912C88C4-8C10-4EBC-E053-F662850A8EB7","latestVersionIndicator":"Yes","beginDate":"2019-08-28","endDate":null,"createdBy":"TSESU","dateCreated":"2019-08-28","modifiedBy":"TSESU","dateModified":"2022-07-07","changeNote":"8/28/19 - smt created for ABTC 1804","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6867039","version":"1","preferredName":"Eligibility Criteria Asthma Or Seizure Uncontrolled Indicator","preferredDefinition":"Indicator of whether patient had uncontrolled asthma or seizures.","longName":"ELIB_ASTHM_SEIZ_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"912AE728-E6A7-7FBA-E053-F662850AED54","latestVersionIndicator":"Yes","beginDate":"2019-08-28","endDate":null,"createdBy":"TSESU","dateCreated":"2019-08-28","modifiedBy":"TSESU","dateModified":"2022-07-07","changeNote":"8/28/19 - smt created for ABTC 1804","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6867043","version":"1","preferredName":"Eligibility Criteria Breast Milk Disposal Agreement Indicator","preferredDefinition":"Indicator of whether patient agreed to dispose of breast milk during the clinical trial..","longName":"ELIG_BRSTMLK_AGM_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9130AD82-1821-707B-E053-F662850A98C6","latestVersionIndicator":"Yes","beginDate":"2019-08-28","endDate":null,"createdBy":"TSESU","dateCreated":"2019-08-28","modifiedBy":"TSESU","dateModified":"2022-07-07","changeNote":"8/28/19 - smt created for ABTC 1804","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6867048","version":"1","preferredName":"Eligibility Criteria Stable Magnetic Resonance Imaging Assessment Indicator","preferredDefinition":"Indicator of whether patient had stable Magnetic Resonance Imaging assessment.","longName":"ELIG_STBL_MRI_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"912B401D-949B-7012-E053-F662850A9F04","latestVersionIndicator":"Yes","beginDate":"2019-08-28","endDate":null,"createdBy":"TSESU","dateCreated":"2019-08-28","modifiedBy":"TSESU","dateModified":"2022-07-07","changeNote":"8/28/19 - smt created for ABTC 1804","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6871997","version":"1","preferredName":"Eligibility Criteria Personal Medical History Or Symptom Severe Sinus Bradycardia Indicator","preferredDefinition":"Indicator of whether patient has medical history or symptom(s) of severe sinus bradycardia.","longName":"ELIB_SNSBRDYCRD_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"91A7BE8C-42A3-7F67-E053-F662850A1868","latestVersionIndicator":"Yes","beginDate":"2019-09-03","endDate":null,"createdBy":"TSESU","dateCreated":"2019-09-03","modifiedBy":"CLOHNES","dateModified":"2022-11-02","changeNote":"9/3/19 - smt created for ABTC 1804","administrativeNotes":"11/2/22 Changed reg status to Application per Janice Knable cjl;","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6986858","version":"1","preferredName":"Eligibility Criteria Disease or Disorder Contrast-enhanced Magnetic Resonance Imaging Measurable Disease Therapeutic Procedure Indicator","preferredDefinition":"Indicator to signify whether or not the patient has measurable constrast-enchancing disease by MRI.","longName":"ELIG_MRI_MEASDIS_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"94E6A45C-FB35-7F59-E053-F662850A9B1D","latestVersionIndicator":"Yes","beginDate":"2019-10-14","endDate":null,"createdBy":"TSESU","dateCreated":"2019-10-14","modifiedBy":"TSESU","dateModified":"2022-07-07","changeNote":"10/14/19 smt created for ABTC 1804 per J. Zsao","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6987701","version":"1","preferredName":"Gadolinium Injection Time","preferredDefinition":"The time gadolinium was injected.","longName":"GAD_INJ_TM","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"94E6E2A4-320F-28D5-E053-F662850A001A","latestVersionIndicator":"Yes","beginDate":"2019-10-14","endDate":null,"createdBy":"TSESU","dateCreated":"2019-10-14","modifiedBy":"TSESU","dateModified":"2022-07-07","changeNote":"10/14/19 smt created for ABTC 1804 per J. Zsao","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6991963","version":"1","preferredName":"Toxicology, Antidotes/Treatment Administered Indicator","preferredDefinition":"Indicator of whether an antidote was administered.","longName":"ANTDTE_ADMIN_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"94E74574-09A3-7D51-E053-F662850A0A50","latestVersionIndicator":"Yes","beginDate":"2019-10-14","endDate":null,"createdBy":"TSESU","dateCreated":"2019-10-14","modifiedBy":"TSESU","dateModified":"2022-07-07","changeNote":"10/14/19 smt created for ABTC 1804 per J. Zsao","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7034808","version":"1","preferredName":"Surgical Patient Clinical Trial Eligibility Criteria Low Grade Glioma To Malignant Glioma Likely Disease Progression Indicator","preferredDefinition":"Indicator of whether surgical patient's low-grade glioma is likely to progress to malignant glioma.","longName":"ELIG_LOHI_PROG_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"962604CC-1949-0452-E053-F662850ADC0E","latestVersionIndicator":"Yes","beginDate":"2019-10-30","endDate":null,"createdBy":"TSESU","dateCreated":"2019-10-30","modifiedBy":"TSESU","dateModified":"2022-07-07","changeNote":"10/30/19 smt created for ABTC 1802","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7169626","version":"1","preferredName":"Eligibility Criteria Donor Spermatozoon Oocyte Negation Agreement Indicator","preferredDefinition":"Indicator of whether donor agreed to not donate oocyte or spermatozoon during clinical trial participation.","longName":"ELIG_EGGSPRM_NO_INC","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9E8E27AF-FD4B-3081-E053-F662850A19DB","latestVersionIndicator":"Yes","beginDate":"2020-02-14","endDate":null,"createdBy":"TSESU","dateCreated":"2020-02-14","modifiedBy":"TSESU","dateModified":"2022-07-07","changeNote":"2/14/2020 smt created for ABTC-1801","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7182248","version":"1","preferredName":"Hepatitis B Hepatitis C Infection Personal Medical History Indicator","preferredDefinition":"Indicator of whether the patient has evidence of active Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV).","longName":"HEP_B_C_NEG_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F53A3A4-34EB-77CB-E053-F662850A9D1F","latestVersionIndicator":"Yes","beginDate":"2020-02-24","endDate":null,"createdBy":"TSESU","dateCreated":"2020-02-24","modifiedBy":"TSESU","dateModified":"2022-07-07","changeNote":"2/24/20 - smt created for ABTC 1701","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7203659","version":"1","preferredName":"Patient Medical Image MRI Count","preferredDefinition":"Number of MRI images.","longName":"MRI_IMG_ CT","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A0ADE190-3A16-0C9D-E053-F662850A0C49","latestVersionIndicator":"Yes","beginDate":"2020-03-12","endDate":null,"createdBy":"TSESU","dateCreated":"2020-03-12","modifiedBy":"TSESU","dateModified":"2022-07-07","changeNote":"Created for ABTC 1801 per N. Danda","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7204259","version":"1","preferredName":"Study Magnetic Resonance Imaging Performed Follow Study Protocol Indicator","preferredDefinition":"Indicator of whether Magnetic Resonance Imaging was performed following study protocol.","longName":"STDY_PER_PRTCL_IND","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A0FBD9A9-1ED2-5D88-E053-F662850A5E40","latestVersionIndicator":"Yes","beginDate":"2020-03-16","endDate":null,"createdBy":"TSESU","dateCreated":"2020-03-16","modifiedBy":"TSESU","dateModified":"2022-07-07","changeNote":"Created for ABTC 1801 per N. Danda","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7204264","version":"1","preferredName":"Magnetic Resonance Imaging Dimensionality Axial Sagittal Type","preferredDefinition":"The response indicating the method, dimensionality and plane used in magnetic resonance imaging.","longName":"MRI_DIM_PLANE_TYP","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A0FC0D5C-E687-5092-E053-F662850A20C6","latestVersionIndicator":"Yes","beginDate":"2020-03-16","endDate":null,"createdBy":"TSESU","dateCreated":"2020-03-16","modifiedBy":"TSESU","dateModified":"2022-07-07","changeNote":"Created for ABTC 1801 per N. Danda","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7222889","version":"1","preferredName":"Neoplasm Mitotic Activity Percentage Range","preferredDefinition":"Percentage range of mitotic activity in neoplasm specimen.","longName":"NEO_MIT_ACT_RNG","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A1D98C4A-55C3-543B-E053-F662850AE7A6","latestVersionIndicator":"Yes","beginDate":"2020-03-27","endDate":null,"createdBy":"TSESU","dateCreated":"2020-03-27","modifiedBy":"TSESU","dateModified":"2022-07-07","changeNote":"Created for ABTC 1801 per N. Danda - smt","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7241620","version":"1","preferredName":"WHO 2016 Classification of Primary Brain Tumor Name","preferredDefinition":"Names of primary brain tumors classified by WHO 2016 Classification.","longName":"WHO2016_PRI_BRTMR_NM","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A2BB71CA-ABDC-7C89-E053-F662850A9973","latestVersionIndicator":"Yes","beginDate":"2020-04-07","endDate":null,"createdBy":"TSESU","dateCreated":"2020-04-07","modifiedBy":"TSESU","dateModified":"2022-07-07","changeNote":"Created for ABTC 1802 - smt","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7241723","version":"1","preferredName":"WHO 2016 Classification Primary Brain Tumor Code","preferredDefinition":"WHO 2016 Classification codes for primary brain tumors.","longName":"WHO2016_PRI_BRTMR_CD","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A2C7FE67-23CA-0E02-E053-F662850A6AC7","latestVersionIndicator":"Yes","beginDate":"2020-04-08","endDate":null,"createdBy":"TSESU","dateCreated":"2020-04-08","modifiedBy":"TSESU","dateModified":"2022-07-07","changeNote":"Created for ABTC 1802 - smt","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7431031","version":"1","preferredName":"Product Infusion Procedure Administered Temporal Frequency","preferredDefinition":"Infusion administration frequency of study agent.","longName":"INFUSE_FQCY","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AFFABC71-91AA-32E8-E053-4EBD850A548E","latestVersionIndicator":"Yes","beginDate":"2020-09-23","endDate":null,"createdBy":"TSESU","dateCreated":"2020-09-23","modifiedBy":"TSESU","dateModified":"2020-09-23","changeNote":"Created for ABTC 1604","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"8177427","version":"1","preferredName":"Total Infusion Procedure Administered Count","preferredDefinition":"The total number of infusions administered to the patient.","longName":"INFSN_TOTAL_CT","contextName":"ABTC","contextVersion":"1","dataElementConceptPublicId":"2768464","dataElementConceptVersion":"1","valueDomainPublicId":"2018550","valueDomainVersion":"1","origin":"ABTC: Adult Brain Tumor Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DD99B593-F1E8-74D1-E053-4EBD850AF449","latestVersionIndicator":"Yes","beginDate":"2022-04-26","endDate":null,"createdBy":"RAGUNATU","dateCreated":"2022-04-26","modifiedBy":"KUMMEROA","dateModified":"2022-08-22","changeNote":"8/1/19 - smt Created for ABTC 1603","administrativeNotes":"2022.8.22 Released. ak","unresolvedIssues":null,"deletedIndicator":"No"}]}